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Résumé 
Une stratégie efficace a été développée pour la synthèse de tours-y inverses, 
particulièrement pour la synthèse de 1,4-diazépin-2-ones et de 1,4-pyrrolodiazépin-2-ones. 
Ces tours-y ont été formés par couplage d'acides N-Boc-a-aminés et d'esters homo-~­
aminés comme précurseurs chiraux facilement accessibles, comme décrit au Chapitre 2. 
Les cétones y,ù-insaturées, intermédiaires clés, ont été préparées par l'addition en cascade 
de bromure de vinylmagnésium sur les N-Boc-a-aminoacyl ~-aminoesters correspondants. 
Par la suite, les 1,4-diazépin-2-ones ont été obtenues par clivage des groupes protecteurs 
Boc, neutralisation des fonctions ammes résultantes et amination réductrice 
intramoléculaire. Ces intermédiaires clés cétones y,ù-insaturés ont été aussi employées dans 
des réactions d'oxydation d'alcènes, comme le procédé Tsuji-Wacker ou des réactions 
d' ozonolyse pour produire respectivement les 1,4-diones et 4-cétoaldéhydes 
correspondantes. Ces composés ont conduit aux 1,4-pyrrolodiazépin-2-ones 
correspondantes après clivage du Boc, neutralisation de l'amine et cyclisation de type Paal-
Knorr. L'accès aux 1,4-diazépin-2-ones possédant un N-substitutant supplémentaire en 
position 1 est décrit dans le Chapitre 3. Les dérivée~ N-alkyl ~-propionate de méthyle ont 
été synthétisées par amination réductrice de quatre différents aldéhydes avec le ~-alaninate 
de méthyle. Les réactions de couplage menées entre ces dérivés alkylés et la phénylalanine 
ainsi que la lysine, toutes deux protégées sur leurs fonctions amines par des groupements 
Boc ont conduit à un certain nombre de dipeptides. Les composés cétoniques ont ensuite 
été obtenus comme précédemment par addition en cascade de bromure de vinylmagnésium 
sur ces N-alkyl a-aminoacyl ~-aminoesters. Les 1,4-diazépin-2-ones 1,3,5-trisubstitutées 
possédant un N-substitutant en postion 1 ont alors été préparés de la même manière selon 
une séquence impliquant le clivage du groupement Boc, la neutralisation de l'amine et 
amination réductrice cyclisante. La présence de N-substituants provoque une accélération 
sensible de l'étape d'amination réductrice pour fournir les diazépin-2-ones 1,3,5-
trisubstituées. Certains résultats préliminaires ont démontré que des 1,4-diazépin-2-one 
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disubstituées peuvent être obtenues à partir des dérivés trisubstitutés comportant un 
substituant acide labile avec de bons rendements. 
Enfin, l'adaptation de cette méthodologie en phase solide a été menée en étudiant deux 
stratégies impliquant l'ancrage des substrats par une fonction amide, comme décrit dans le 
Chapitre 4. Les tentatives employant un linker de type mercaptoéthyle sur une résine 
polystyrène ont été infructueuses. Alternativement, une 1,4-diazépin-2one a pu être 
synthétisée en employant une résine aldéhyde de Wang suivant six étapes similaires à celles 
décrites au Chapitre 3. Le clivage final est effectué par traitement acide, tel que par le TFA, 
pour fournir un produit brut de haute pureté. Les conformations des tours occasionnées par 
ces 1,4-diazépin-2-ones ont été déterminées par diffraction de rayons X. 
En résumé, ces travaux ont permis d'aboutir à de nouvelles méthodologies en solution et 
sur support solide permettant l'accès à des dérivés de type diazépin-2-one. Ces 
méthodologies peuvent de plus potentiellement conduire à des composés de plus grande 
diversité moléculaire en vue d'éventuelles applications thérapeutiques. 
Mots clés: Tours-y, peptidomimétiques, cétone, résine amide, double addition de réactifs 
de Grignard vinyliques, antibiotiques. 
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Abstract 
An efficient strategy has been developed for the synthesis of inverse y-tum mlmlCS, 
particularly 1,4-diazepin-2-one and 1,4-pyrrolodiazepin-2-one heterocyc1es. The tum 
mimics were assembled from the coupling of N-Boc-a-amino acids and homo-~-amino 
esters as inexpensive chiral building blocks, as described in Chapter 2. The key 
intermediate y,ô-unsatured ketone was prepared by the cascade addition of vinyl Grignard 
reagent to the corresponding N-Boc-a-aminoacyl ~-aminoester. Subsequently, Boc group 
deprotection, amine neutralization and intramolecular reductive amination yielded the 1,4-
diazepin-2-one skeleton. The key intermediate y,ô-unsatured ketone could also be 
employed in alkene oxidations by the Tsuji-Wacker process and by ozonolysis to 
respectively yield 1,4-diones and 4-ketoaldehydes, which upon Boc group removal, amine 
neutralisation and Paal-Knorr cyc1isation yielded 1,4-pyrrolodiazepin-2-ones. 
Access to the 1,4-diazepin-2-one possessing an additional N-substituent at the I-position 
was achieved as described in Chapter 3. Methyl N-alkyl ~-aminopropionate derivatives 
were synthesized by reductive amination of the imine generated from methyl ~-alaninate 
and four different aldehydes. Dipeptide formation followed by addition of vinyl Grignard 
reagent to the N-alkylated a-aminoacyl ~-aminoester yielded y-ô-unsatured ketone. 
Trisubstituted-l,4-diazepin-2-ones possessing a I-postion N-substituent were the~ prepared 
by an analogous Boc deprotection / amine neutralisation / reductive amination sequence. 
The additional N-alkyl substituent caused a noticeable acceleration in the reductive 
amination step to provide the 1,3,5-trisubstituted diazepin-2-ones. Preliminary results 
demonstrated that disubstituted 1,4-diazepin-2-one can be made from the trisubstituted 
analog bearing acid labile N-substituent in good yield. 
Finally, the adaptation of our solution-phase methodology to solid phase was pursued 
studying two different backbone amide linker strategies, as discussed in Chapter 4. 
Attempts were unsuccessful in employing a mercaptoethyl linker on polystyrene resin. 
Altematively, 1,4-diazepin-2-one was synthesized on Wang aldehyde resin by a 6-step 
process similar to that described in Chapter 3 featuring c1eavage from the resin by treatment 
v 
with acid, such as TFA, to provide the crude product ofhigh purity. The tum conformations 
of 1,4-diazepin-2-ones were determined by x-ray structures analysis. 
In summary, this thesis has provided new methodologies for making diazepin-2-one 
derivatives using solution and sol id-phase chemistry and offers potential for synthesizing 
such y-tum mimics for future studies in peptide science and medicinal chemistry. 
Key Words: y-tum, peptidomimetics, y-ô-unsaturated ketone, 1,4-diazepin-2-one, 
backbone amide linker, cascade addition of vinyl Grignard reagent, antibiotics. 
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Chapter 1 1 
CHAPTERI 
INTRODUCTION 
Chapter 1 2 
1.1 Peptides as Drugs 
Endogenous peptides and proteins such as the enkephalins, angiotensin II, bradykinin, 
cholecystokinin and insulin were shown to control many of the chemical and physiological 
processes in the human body. Most exert their biological function at specifie receptors, in 
particular seven transmembrane G-protein coupled receptors (GPCRS).1,2 
Discovery of biologically active peptides and proteins with relevance in disease processes 
has led to the discovery of novel therapeutic targets, as weIl as probes for the development 
of new drugs.3 A significant increase over the last decade in the use of peptides as agonists 
and antagonists for the development of drugs has been observed. However, in most cases 
the use of native peptides as therapeutic agents has been limited due to poor 
pharmacokinetics, such as difficulty in crossing the blood-brain barrier, low uptake, poor 
oral administration, rapid metabolism and facile excretion. Furthermore, the flexibility of 
the peptide may also reduce receptor specifity.4,5,6,7 Significant efforts have been committed 
to the design and synthesis of non-peptidic molecules which display pharmacologie al 
activity like the native peptides at their receptors to avoid the above problems. These non-
peptidic compounds are referred to peptidomimètics. 
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HO 
HO'" 
R = CH
3 
(morphine) 
R= ~ (nalorphine) 
Figure 1.1 Morphine (opiate agoni st) 1 and nalorphine (opiate antagonist) 1 compared with 
enkephalins 2. 
An example of peptide mimicry is that of morphine, which acts as a non-peptide agoni st 
producing a similar agonist effects and binds to the same receptor family compared to the 
corresponding endogenous peptide enkephalins (Fig 1.1). The possible structural 
relationship between the morphine skeleton and enkephalins remains unknown. 8 Morphine 
and related opioids remained the only examples of non-peptide agonists at peptide receptors 
for an extended period of time. It is only in the past few years that other examples of non-
peptide agonists or antagonists at peptide receptors have been reported (Fig. 1.2).9 
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AT 1 receptor antagonist 
Br~ S 
~._A )l H 
N/. N~N N~N" 
Jj H H li; ~ N Ih-Cl 
Cl 
Somatostatin sst4-receptor agoni st 
CCK1 receptor antagonist 
~-P~ lr1 -
H2N~N N 0 
Weak sst-receptor partial agonist 
Figure 1.2 Examples of non-peptide agonists and antagonists. 1O 
1.2. Peptidomimetics 
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Peptidomimetics are valuable research tools for the study of molecular recognition by 
structure-activity relationship (SAR) investigations.8,1I Constrained structures that mimic 
the bioactive conformation of a peptide may be more resistant to enzymatic cleavage and 
exhibit enhanced selectivity compared to the linear flexible peptide.8,12 
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Peptidomimetics can be c1assified into three types: 
Type 1: Mimetics which match the peptide backbone. These are peptides which are 
modified by an amide bond isosteres. 
Type II: Small nonpeptidic molecules that bind to a peptide receptor or enzyme. 
Type III: Nonpeptidic molecules unrelated to the original peptides which may be 
considered as ideal mimetics containing the functional groups necessary to serve as 
topographical mimetics. 13 Several approaches have been described for the development of 
peptidomimetics, sorne ofthem are listed below. 
1.2.1. Side-Chain Modifications 
The incorporation of amino acids with side chains that do not occur naturally in peptides 
and pro teins may introduce special functional groups, restrict peptide flexibility and 
increase metabolic stability.14 Such single residue modifications inc1ude enantiopure N-
alkyl and Ca-dialkyl amino acids. For example [l-deamino, D-arg8] vasopressin (DDAVP) 
is a modified peptide used as a selective antiduretic agent suitable for the treatment of 
diabetes insipidus.6 
1.2.2. Backbone Modification 
In addition to the backbone modifications caused by single residue substitutions, the 
replacement of peptide bonds by non-peptide analogs has also been utilised to modify the 
backbone of peptides. Such isosteric replacements inc1ude substitution of the amide by 
hydroxyethylene, vinyl ester and amine moieties, as well as the replacement of the u-
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carbon by nitrogen in azapeptides or by a BR group in borapeptides. The most general 
modifications are listed in Table 1.1. 
Exchange of the individual units Extension of peptide chain Replacement of the 
R 
amide bond 
R 
1 
---1 CO-NH r-NH ~ ~O -NH -CH-CO-
--ŒJ- ---{il- ---{ru- --ŒJ- ---1 NH-CO r-
depsi aza endothiopeptide retro-inverso 
----ITJ---- ~ ---Œffi---- -lCH(OH)-CH} 
thioester ketomethylene 
hydroxyethylene 
-(CO)-[lliJ- ----G!!}- ~ ----{Qhl- ~HC=CH-
ketomethylene bora sulfinamides, n=1 (E)-alkene 
sulfonamides,n=2 
---1 P=O(OH) ~ +CH2-CH2t 
phosphonamide carba 
Table 1.1 The most frequent modifications of the peptide backbone.' , 
1.2.3. Restriction by Cyc1ization 
Global restrictions in the conformation of a peptide may be achieved by backbone 
cyc1ization. Cyc1ic peptides may possess relatively rigid conformations, decreased 
molecular volume, increased metabolic stability, superior bioavailability and higher cell-
permeability.'4 
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1.2.4. Secondary Structure Mimetics 
The secondary structure of a protein refers to the folding of local regions into energy-
minimum conformations that are stabilized by non-covalent bonds such as hydrogen bonds 
and hydrophobic interactions. Hydrogen bonds are formed between the NH group 
(hydrogen bond donor) and the carbonyl oxygen atom (hydrogen bond acceptor) of peptide 
amide bonds. Common secondary structural motifs inc1ude the: a-helix, ~-sheet, and tum 
conformations. Incorporation of such a moiety will provide additional information about 
the condition of receptor binding and activation. Secondary structures such as tums are 
often essential components for peptide and prote in biology because they are often located 
on the prote in surface and act as molecular recognition sites. 10,14,15 
1.3. y-Turn 
The y-tum is a secondary structure that contains three amino acid residues connected by 
amide bonds. In the y-tum a hydrogen bond may exist between the backbone carbonyl of 
the first residue (i) and the amide NH of the third residue (i+2), to form a seven-membered 
ring (Fig 1.3). The y-tum has been c1assified into two families, contingent on the dihedral 
angles (~and\lf), of the central amino acid residue (Fig 1.3).16-21 
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Classic 
~i+ 1 700 to 850 
'JI i+ 1 -600 to -850 
Inverse 
_700 to -850 
700 to 850 
Figure 1.3 Classic and inverse y-tums with their corresponding angles. 
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The inverse y-tum is found more frequently than the classic y-tum. The inverse y-tum does 
not give rise to chain reversaI in proteins, inverseIy to the classic tums. y-Tums are rare in 
proteins, however, they are often found in sm aIl cyclic peptides (Fig 1.4).16,18 
:~:NHTrt 
}-O~ 
o 
3 
H Me Me'(}o 
Ph~H 
N CONH2 Mpa-Tyr-N ~ 
H 0 T~~ 
HN 0 
H2NCO'-.\\\.yc s-Pro-D-Arg-Gly-NH2 
o 
Me 
5 6 
Figure 1.4 ExampIes ofheterocyclic and peptide y-tum mimetics (323,46,52\ and 66). 
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y-Tums have been shown to play important roles in the control of local peptide 
conformations and also in biological recognition.22 For example, the y-tum present in the 
RGD (Arg-Gly-Asp) sequence of vitronectin was found to contribute to the specific 
recognition of integrin receptor av~3.25 Several linear and cyclic peptides that exhibit 
biological activity such as bradykinin, cyclosporin, vasopressin and the cyclic somatostatin 
analogues have been shown to adopt y_tumS.24,26 
Sorne of these molecular scaffolds have been incorporated into biologically active peptides 
to study the relationship between conformation and activity. For example, the incorporation 
of an inverse y-tum in place of residues 3-5 in the peptide hormone oxytocin produced an 
analog that did not induce contractions of the uterine tissue nor did it act as an inhibitor of 
oxytocin-induced contractions.27 However, the incorporation of 2-oxo piperidines as y-tum 
mimetics into the bradykinin sequence produced an analog with an activity similar to 
bradykinin and so this supported the presence of a reverse y-tum in the bioactive 
conformation of this peptide.24 
1.4. 1,4-Diazepinones and Pyrrolodiazepinones 
The benzodiazepines (BZDs), which include the diazepam better known as Valium® 7 and 
alprozalam 8 (Fig 1.5) are an important class of drugS.28 Benzodiazepines exhibit different 
therapeutic applications such as antitumor antibiotic, muscle relaxant, HIV Tat antagonist, 
hypnotic and anxiolytic activities, due to their potential to mimic peptide secondary 
structures such as y- and ~- tums.29 Benzodiazepines are known to exert their broad 
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pharmacological effects through specific binding to a subunit on the y-aminobutyric acid 
which acts on the y-aminobutyric acid-A chloride ion channel (GABAA) receptor.30 
Furthermore, it has been suggested that benzodiazepines, such as diazepam, may be 
peptidomimetics of endogenous peptide endozepines which are single-chain polypeptides 
of 86 residuesY The seven-membered ring in a benzodiazepine can be formed as acyclic 
dipeptide.32 
Cl 
Diazepam 
7 
Alprazolam 
8 
Figure 1.5 Structure of diazepam and alprozalam. 
1,4-Benzodiazepine heterocycle fused diazepine derivatives such as 1,4-diazepinone and 
pyrrolobenzodiazepinone derivatives (Fig 1.6) have exhibited widespread biological 
activities.33 Examples have been reported for 1,4-diazepinones that act as inhibitors of the 
lymphocyte function-associated antigen-l (LF A -1 )34 and as anticonvulsant agents.35 The 
diazepinone system is also present in the liposidomycin nucleoside antibiotics which inhibit 
bacterial peptidoglycan synthesis.36 Furthermore, 1,4-diazepinone derivatives have been 
incorporated into peptides as constrained dipeptide mimetics.37 
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Ph 
cC} 
/ 0 
Pyrrolodiazepinone 1,4-Diazepin-2-one Benzodiazepine 
Figure 1.6 Structure relationship between pyrrolodiazepinone, 1,4-diazepin-2-one and 
benzodiazepine. 
The pyrrolobenzodiazepines (PBDs) are a group ofnaturally occurring antibiotics produced 
by diverse Streptomyces species, which include the anthramycin family, that contain a 
pyrrolobenzodiazepine structure.38 Synthetic pyrrolobenzodiazepines analogs have 
inhibited non-nucleoside reverse transcriptase.39 Activity was also demonstrated against 
various leukemia celllines40 and as CNS antidepressants41 (Fig 1.7). The seven-membered 
1,4-diazepinone ring adopts a y-tum conformation,42,43 as supported by X-ray diffraction.44 
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LFA-l inhibito?4 Tomaymycin antibiotics3& 
o 
r,NH 
N~ 
o 
HO 
HIV reverse transcriptase inhibitor39 
Figure 1.7 Examples of 1,4-diazepinones and 1,4 pyrrolodiazepinones. 
1.5. Diazepinone Synthesis 
The synthesis of diazepinone ring systems has attracted considerable interest in developing 
probes for studying structure-activity relationship of biologically relevant receptors. There 
are a variety of approaches for the synthesis of 1,4-diazepinone ring systems. 1,4-
Diazepinones have been synthesized through head-to-tail cyclization of the terminal amine 
and carboxylic acid moieties of a linear dipeptide consisting of an a-amino and p-amino 
acid, using an activating agent. 
Chapter 1 13 
1.5.1 Diazepinones Synthesis by Lactam Formation 
Trisubstituted 1,4-diazepin-3-one was synthesized for use as a novel constrained dipeptide 
scaffold (Scheme 1.1, synthe sis 1). The synthesis began from readily available N-protected 
homo serine lactone 10. Ring opening of lactone 10 by aminolysis generated the primary 
alcohol 11 which was oxidized to the corresponding aldehyde 12 using pyridinium 
chi oro chromate (PCC) in the presence of silica gel. The reductive amination of aldehyde 12 
with t-butyl-(S)-phenylalaninate using sodium cyanoborohydride in methanol afforded the 
secondary amine 13. Acylation of the secondary amine 13, followed by Boc removal and 
lactam formation yielded 1,4-diazepinone 15. This acylation of the secondary amine 13 
resulted in a mixture of isomers, generated by the GÏs-trans isomerisation around the 
acetylated tertiary amide bond. A closely related synthesis of diazepinone 15, was 
accompli shed from N-protected aspartic acid 16, using similar protocols featuring a 
reductive aminationllactam cyclization sequence (Scheme 1.1, synthesis 2). The yield 
obtained for diazepinone 21 was low and several side products were obtained in the last 
step of the synthesis.37 1,4-Diazepin-2-one has been prepared in enantiomerically enriched 
form as a constrained peptide mimic from chiral BocGlu(Obzl)OH 22. Methylation, 
debenzylation and modified Curtius reaction yielded diamino acid 23. Boc removal, N-
tosylation and N-alkylation followed by t-butyl removal and lactam formation gave 1,4-
diazepin-2-one 25 in moderate yieid (Scheme 1.1, synthesis 3).45 
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Synthesis 1 
Htl'O H, 1'0 
HC1.H2N~ -------
O 76% 
(t-Bu-OCOhO, Et3N 
DMF t-Bu-OCOH2N~ 
o 
10 
MezNH 
EtOH-THF 
70% 
9 
PCC/silica gel [ 
DCM • 
1 NM~] HCI t-Butyl (S)-Phenylalanine t-BU-OCOH2~/~ _N_a_C_NB_H_3_, A_c_O_H_-_M_e_O_H __ _ 
o 
12 54% for two step 
O\~n~./H 1\ 1) TFA in DCM 
AC20, i-Pr2NEt, DMAP 
chloroform H, NMe2 ____ D_Mf ____ _ 
t-BuO ACN~ 2) (PhOhP(0)N3' NaHC03 
t-Bu-OCOH2N 79% 
14 0 
80% 
Synthesls 2 
OH 
1) t-Bu-OCOCI, Et3N ~C02H THF H, , O-t-Bu ..;;2;.:.).:.N;:;;aB:;;,H=4 • ..:,H::.;.20.::::-__ H, ,,) O-t-Bu BnOCOHN~ PCC/silica gel DCM BnOCOHN o 67% o 
16 
0p<H 
17 
HCI t-Butyl (S)-Phenylalanine 
NaCNBH3, AcOH-MeOH H" O-t-Bu 
BnO HN~ HC02-NH/, 10 % PdlC 
MeOH-AcOH-H20 
BnOCOHN 
19 0 97% 67% 
H Bn 0 1--f 
HN NH ~, .. t.. -O-t-Bu 
21 H" Tr 
HATU, I-Pr2NEt, DMF 
40% 
Synthesis 3 
BocGlu(OBzl)OH 
22 
o 
1) IBCF, Et3N, MeOH 
2) H2' Pd(OH)2' EtOH 
3) DPPA, Et3N. PhCH20H 
50%overal1 
W (NH3+Sr" 
DMF MeO~ 0 TSN~OH 
24 
50% 
o 
)l /"... ,NHZ 
MeO' l "-/ 
NHBoc 
23 
o 
MeOÂ(\NH 
Ts" .... N~ 
2S 0 
l)TFA 
2)TsCl 
3) BrCH2C02tBu, CHlCN 
18-C-6, K2C03 
4) AcOH. TFA 
78% overall 
Scheme 1.1 Diazepinone synthesis by lactam formation. 
14 
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1.5.2 Diazepinones Synthesis by Mitsunobu Cyclisation 
Racemic 1,4M diazepin-2-one has been prepared as a constrained peptide mimic starting 
from N-Boc-allylamine 26. Dipolar cycloaddition afforded isoxazolidine 27. Ring opening 
N-acylation yielded the linear precursor 29. Intramolecular cyc1ization of 29 was then 
accomplished under Mitsunobu conditions for the alkylation of sulfonamide 29 to afford 
1,4-diazepin-2-one 30. The cyclization of a tertiary amide was essential for ring formation. 
BocHN~ 
26 
30-82% 
RI = H, CH2Ph, CH) 
78-94% 
BocHNy.-o, 
~N-Rl 
27 
RI R2 
BOCHN~~0NHTS 
OH 0 
29 
R2 = CH), CH2Ph CH20CH2Ph, CH2CH(CH3h 
79-99% 
1) PPh), DEAD 
2)TFA,DCM 
0-97% 
H 
BOCHN~N'RI 
OH 
28 
Scheme 1.2 1,4-Diazepin-2-one synthesis by Mitsnubou cyc1ization.45 
1.5.3 Diazepinone Synthesis by Parallel Approaches 
The liposidomycins are a family of nuc1eoside antibiotics with complex structures 
composed of three portions: a diazepinone moiety, an aminopentose moiety and a lipid 
portion. There have been different procedures describing the synthesis of the diazepinone 
moiety with the aim of developing liposydomycins analogs as new antibacterial drugs that 
inhibit the enzymes responsible for the biosynthesis of bacterial peptidoglycan. 
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Formation of the N,N-dialkyl diazepinone 33 core was accomplished by a one-pot synthesis 
featuring heating a mixture of N,N-dimethylpropane-1,3-diamine 31 and the sodium 
bisulfite adduct of glyoxal 32 at reflux in toluene (Scheme 1.3). This approach was later 
abandoned because of the harsh conditions employed that led to epimerization and 
e1imination in the case of more substituted diazepinone. 
NaHC03aq, toluene, reflux 
40% 
32 33 
Scheme 1.3 Synthesis of N,N-dimethy11,4-diazepin-2-one 33. 
The 7-substitued 1,4-diazepin-2-one 37 was later prepared by a synthetic route featuring 
annulation by reductive amination (Scheme 1.4). N-Boc-sarcosine ethyl ester 34 was 
converted to its lithium enolate, alkylated with ally1 iodide, N-deprotected then acylated 
with N-(Cbz)-sarcosine to afford dipeptide 36. Oxidative cleavage of the olefin gave 
aldehyde 37, which was hydrogenated to remove the Cbz group allowing intramolecular 
iminium ion formation and reductive amination to yield diazepinone 38. 
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o CH3 )~N, 
EtO CO2-t-Bu 
1) LDA, THF, -78 oC 
2) Allyl idodide, -20 oC 
34 84% overall 
)O~~~3 EtO COrtBu 
1 35 
1) TFA/DCM 
2) N-Cbz-sarcosine 
DIPC, HOBt, DCM 
76% overall 
17 
o CH
3 
_______ .. Et°5-)=N
CH
o
3 
EtOH)NYNO_CH H2' Pd-C, MeOH l~ 
~ 67% from36 
36 
1 3 H3C o C02Bn 
37 38 
Scheme 1.4 Synthesis of l-substitued 1,4-diazepin-2-one 37 .46 
1.5.4 Diazepinone Library 
A library of ninety 1,4-diazepin-2-ones was synthesized starting from a-amino amide 39 
(Scheme 1.5). Michael addition onto the methyl vinyl ketone gave secondary amine 40; 
which was acylated with an N-Boc amino acid and N-deprotected to yield dipeptide 41. 
Intramolecular reductive amination yielded diazepinone 42, which was acylated to afford 
diazepinone 43 with overall yield of 5- 10%. 
o 0 H )l . NH2 HCI Methyl vinyl ketone, dioxane )l. 1) Boe amino aeid, DIPC, NMM, DMF, rt 
2) TFA neat, then 3N HCI/ diethyl ether H2N Y . DIPEA H2N Y N~( 
RI ---------~ 1 RI 0 ------------~ 39 
NaBH3CN, dioxane-H20 
pH 5.4 
40 o 
R)lOH 
DIPEA, EADC, DCM, rt 
5-10% overall 
RI = (S)·Me, (R)-Me, (R)-Benzyl, (S)-Benzyl, (S)-2-Naphtalenylmethyl, (S)-2-indomethyl 
R2 = (R)-Me, (S)-iBu, (R)-iBu, (R)-Cyelohexylmethyl, (R)-2-Phenylmethyl 
R3 = 2-Naphtalenylmethyl, I-Naphtalenylmethyl, N-Benzyl 5-indolylmethyl 
Scheme 1.5 General synthesis oflibrary of 1,4-diazepin-2-one 43. 34 
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1.5.5 1,4-Diazepinones Synthesis By Ring Expansion 
The 1,4-diazepin-5-ones were synthesized by a route featuring ring expansion by an azido-
Schmidt reaction (Scheme 1.6). Piperidones 45 reacted in the presence of an acid and with 
2-hydroxyalkyl azides 44 to yield a hemiketal intermediate that underwent the azido-
Schmidt reaction to fumish cyclic iminium ether 46. Subsequent hydrolysis produced the 
desired 1,4-diazepin-5-ones 47. Enolization and alkylation of 1,4-diazepin-5-one 47 yielded 
a mixture of diastereoisomers 48. 
6 O>"'R _B_F_3_0_E_t2_/T_fD_H~ /::)N KOHINaHC03 lN 52-89% overall 
44 45 X 
1) NaH, BnBr, DMF 
2) LiHMDS-HMPA, BnBr, THF 
45 % overall for R = CHMe2 
X 46 
x = Bn, Cbz, Fmoc, GlyCbz 
R = CHMe2, CH2CHMe2, CH2C6H40Bn, 
(CH2hNHCbz, (CH2hSMe, C02Bn, 
Scheme 1.6 Synthesis of 1,4-diazepin-5-ones 47 by azido-Schmidt reaction.42 
Intramolecular ring expansion has proven to be a versatile method for the synthesis of 
diazepinones. For example, intramolecular transamidation has been used to prepare 1,4-
diazepin-5-ones (Scheme1.7).43 Heating iminoketimines 51 in toluene at reflux, provided a 
mixture 1:1 of cis and trans azeto[I,2-a]imidazoles 54 and 55. Purification of the crude 
mixture by chromatography on a silica gel column yielded trans-diazepinones 52 and cis-
azeto[I,2-a]imidazoles 53. The cis-azeto[I,2-a]imidazoles 53 could be converted to cis-
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diazepinones 56 with catalytic HCI in THF/H20. In an aternative strategy four N-
aminoethyl-p-Iactams, 57 and 58 were prepared by intramolecular 2+2 cycloadditions; 
however only the Gis isomer reacted to provide diazepinone 52 by intramolecular 
transamidation. 
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NH2 
( Ar-CHO, MgS04, Et20, rt 
N 3 
Ar 
Nd 
( PPh3, Et20, reflux 
N 3 
49 
Ar 
Nd 
( Ph(CH3)C=C=O ~ 
N=PPh3 
50 
Ar 
Nd 
( ;-CH3 
N=C=C 
"Ph 
51 
20 
1) Toluene, reflux 
2) Silica gel colurnn 
H H 
N1
Ar C '",CH3 
N Ph + 
~1H'Ar r-J+A< ( , "Œ, 
\ _ HCI cat, THFIH20 rt N Ph N-- , , 'Ph ------'-----=--.... H ° 
H ° 
CH3 
trans-52 1; 1 Ratio cis-53 
17-24 % overall 20-26% overall 
1 Sili", 001 ,olumn 1 
Ar H 
Nd /"~ 
( 
Toluene reflux ~ \ _ N "'Ar + 
51 ;-CH3 N-- "'CH3 
N=C=C Ph 
"Ph trans-54 
1) Ph(CH3)C=C=O, DCM, rt, 
2) PPh3, THF, reflux 
3) H20, THF, rt 
Ar = 4-CI-C6H4, 4-Br-C6H4, 
3,5-(CH30)z-C6H3, 4-02N-C6H4 
H 
<-~~'''Ar N~--+"Ph 
CH3 
cis-55 
H 
k~~"'Ar 
2n "'CH3 
° CH3 
trans-58 
32-43 % overall 
+ H 
"A"'Ar NH 2 "'Ph 
° CH3 
55 cis-57 
14-20 % overall 
Toluene reflux 
Toluene reflux 
Il 
cis-56 
16-22% ove rail 
+ H 
r-A"'Ar 
"'Ph 
H2N ° CH3 
cis-57 
42-59% overall 
~1H'Ar C '",CH3 
N Ph 
H ° 
trans-52 
34-40% overall 
~1H'Ar C '",CH3 
N Ph 
H ° 
cis-56 
Scheme1.7 Synthesis of 1,4-diazepin-5-ones by ring expansion and intrarnolecular 
transarnidation.43 
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1.5.6 Pyrrolodiazepinones Synthe sis 
Although pyrrolodiazepinones fused to a third aromatic or heteroaromatic ring have been 
reported, to the best of our knowledge only one synthesishas been described which affords 
the parent pyrrolodiazepinone (Scheme 1.8). paal-Kno) condensation of phtalimidoalkane-
1,4-diones 59 and glycine ethyl ester gave (phtalimidoalkyl)pyrrole 60. Hydrazinolysis 
removed the phtalimide and intramolecular acylation yielded pyrrolodiazepinones 62. 
~o /'--.. 1 /'--... RI N "'" '1 l( + ~ R 0 
o 59 
R 
rQ 
HNy RI 
o 62 
60 
First example R = H and RI = CH3 yield 27% 
Second example R = C6Hs and RI = C6Hs yield 37% 
Scheme 1.8 Pyrrolodiazepinones synthesis.47 
1.5.7 Solid-Phase Synthe sis of Diazepinones 
The synthesis of diazepinones on solid-phase has attracted attention in order to prepare 
libraries of these heterocycles. For example, diazepinones were made from a linear 
precursor 65 generated by N-alkylation of the tert-butyl phenylalaninate with resin-bound 
co-bromo-a-aminobutanoamide 64 and selective removal of the Fmoc and tert-butyl 
groups. Lactam formation and resin cleavage yielded diazepinone 68 (Scheme 1.9). 
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H, 1'0 
Fmoc.HN~ 
o 
HBr/ AcOH 
B~r 1) H-pMBHA-~ 
H, OH DCCII HOBt IN DMF 
FmocHN _2)::...,A_c..::,20 ____ _ ~ '-' FmocHN CO-pMBHA ~
o 
63 ~l 
:::".. 
64 65 
O-tBu 1) 20 % piperidine in DMF 
2) 40 % TFA / anisole (95:5) in DCM 
H, ~ 
FmocHN CO-pMBHA ~ 
r'i 
:::".. 
OH 1) BOP/ DIPEA in DMF 
H, ~ 
H2N CO-pMBHA ~ 
66 
H --l-NH2 &:~ 
67 
pMBHA -0 = p-methylbenzhydrylamine resin 
Scheme 1.9 1,4-Diazepin-3-one synthesis on solid support.48 
Ring expansion of piperidone 69 attached to Merrifield resin was accompli shed using 3-
azidopropanol in a solide-phase azido-Schmidt reaction (Scheme 1.10). Esterification with 
N-Boc phenylalanine and resin cleavage gave diazepinone 71. 
N3~OH 
1) BF3.OEt2' DCM 
2) H30+ 
3) n-Boc-Phe-OH, DCC, DMAP 
71 
33% overall yield 
Scheme 1.10 Solid phase syntheis of diazepinones by ring expansion.45 
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Finallya library of 1,4-diazepin-2-ones were prepared using a-amino acids linked to Rink-
amide MBHA resin. Michael addition to methyl vinyl ketone, acylation with a second 
amino acid and reductive amination gave diazepinone 75. Acylation of the resulting 
heterocycle 75 yielded an expanded set of diazepin-2-ones 76 (Scheme Il). 
o Jl 1) 20 % piperidinelDMF ~ N' Y NHFmoc 2) Methyl vinyl ketone, DMt' 
Fmoc-amino acid, HOBt, 
@NH2 DIPEA 
RinkMBHA 
J3.2 
/'.. HOlC NHFmoc 
DICD,DMF 
1) HOlCR), DICD, DMF 
2)TFAlDCM 
H RI 
J3.2 72 
o . 
o ~NHFmoc 
~NÂyN~ 1) 20 % piperidinelDMF 
H RI Ô 2) NaBH)CN, DMF 
74 R2 0 
O~ )l.RJ o 1 N X=NH2,OH XÂyNJ''''~6 
RI 
RI = (S)-Me, (R)-Me, (R)-Benzyl, (S)-Benzyl, (S)-2-Naphtalenylmethyl, (S)-2-indomethyl 
R2 (R)-Me, (S)-iBu, (R)-iBu, (R)-Cyclohexylmethyl, (R)-2-Phenylmethyl 
R3 = 2-Naphtalenylmethyl, I-Naphtalenylmethyl, N-BenzyIS-indolylmethyl 
Scheme 11 Diazepin-2-one library generated by solid-phase synthesis.34 
1.6 Aims of the Project 
This study is part of an ongoing research project with the overall goal of developing new 
methodologies for the synthesis of diazepinone heterocycles using solid-phase and solution 
reactions. The solution 'chemistry utilizes a-amino acids 77 and ~-amino esters 78 as 
inexpensive, commercially available starting materials to provide a-aminoacyl ~-amino 
esters 79 (Scheme 12). The homoallylic ketones 80 were obtained from a Cu-catalyzed 
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cascade addition of a vinyl Grignard to esters 79. This methodology developed by Lubell 
and co-workers, provided pyrroles in two steps from the homoallylic ketones by olefin 
oxidation of a 1,4-dicarbonyl compound and Paal-Knorr condensation with vanous 
primary amines.49 Homoallylic ketone 80 was then used as a precursor for making 
diazepinone 81 and pyrrolodiazepinone 83 heterocycles. 
o R3 0 
Peptide coupling • Rlyl~~lo/ 
BocHN j 79 
Homoallylic ketone synthesis 
Reductive amination 
.. 
Paal-Knorr condensation 
R, = CH3 , Bn, CH20H 
R2 = H, CH3 
R3 = H, Bn 
o R3 0 
Rlyl~~~ 
BocHN 
80 j Wacker or 
Ozonolysis 
Scheme 12 General methodology for making diazepinone and pyrrolodiazepinone. 
The 1,4-diazepin-2-one was generated on ammo ethylated polystyrene resm (AEPS). 
Coupling of the resin to para-mercaptobenzoic acid derivatives gave polymer supported 
resin 84. Acetal deprotection, followed by reductive amination with ~-amino esters gave 
the secondary amine supported resin 85. The secondary amine 85 was acylated using 
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activated Boc ammo acids. Cascade addition of vinyl Grignard to the resulting tertiary 
amide 86 yielded homoallylic ketone supported resm 87. Sulfone oxidation, Boc 
deprotection, intramolecular reductive amination and p-elimination produced diazepinone 
88. Pyrrolodiazepinone 90 was obtained by oxidation, Boc removal, and intramolecular 
Paal-Knorr cyclization and p-elimination. The general pathway is presented below in 
Scheme 13. 
c::. Peptide coupling 
V-NH2 • 
MeO 
('"l;\ H JLJ=L f OMe WN~S 
o 
Acetal de protection ('"l;\NH JLJ=LSJH 'W~ 
83 ~c02Me 
Reductive amination. @-~JlQ-S~NH Peptide coupling • 
85 q,/ 
~c 1) Sulfone oxidation 
~ 2) Boe de protection 
('"l;\ HJLQ--° ~N 3) Cyclization 
Cascade addition WN ~ /; s )=0 4) ~-elimination 
• Rl--\ 
87 NHBoc 
Oxidation R
2 q,J-\ 
~c 0 
H~~~N ~N~S >=0 
89 
Rl--\ 
NHBoc 
1) Sulfone oxidation 
2) Boe de protection 
3) Cyclization 
4) B-elimination 
86 
R1 = CH3, Bn, CH20H 
R2 = H, CH3 
R3 = H, Bn 
84 
Scheme 13 General methodology for making diazepinone and pyrrolodiazepinone using 
a traceless linker. 
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l,4-Diazepinone 95 and pyrrolodiazepinones 98 and 99 were synthesized from common 
homoallylic ketone precursors 94 prepared by copper-catalyzed cascade addition of vinyl 
Grignard reagent to a-aminoacyl p-amino-esters 93. Nitrogen deprotection~ and 
intramolecular reductive amination yielded 1~4-diazepinones 95. Olefin oxidation, Boc 
removal and intramolecular Paal-Knorr condensation gave pyrrolodiazepinones 98 and 99. 
X-ray structures of diazepinones 95c and 95d depicted dihedral angles about the a-amino 
acid moiety similar to the central residue in an ideal reverse y-tum. 
2.2 Introduction 
Among the small molecules employed in drug discovery, molecular scaffolds that mimic 
peptide secondary structures are particularly useful for lead identification and the 
development of therapeutic agents. In this respect, l,4-benzodiazepines display a wide 
range of pharmacological activities likely due to their potential to mimic peptide turn 
conformations. 1-3 1~4-Diazepinones have exhibited activity as high-affinity antagonists of 
the lymphocyte function-associated antigen-l / immunoglobulin superfamily ICAM-l 
interaction.4 They have shown anticonvulsant activity.5 The diazepinone system is also 
present in the liposidomycin nucleoside antibiotics that inhibit bacterial peptidoglycan 
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synthesis (Figure 1).6 The pyrrolobenzodiazepine structure is contained in the natural 
anthramycin family of antitumor antibiotics.7 Synthetic pyrrolobenzodiazepines have acted 
as non-nucleoside reverse transcriptase inhibitors8 and CNS agents;9 they have also 
exhibited antiproliferative lO and antidepressantll activity (Figure 1). The synthesis of 
diazepinone ring systems has attracted considerable interest. Annulation of the diazepinone 
\ 
ring has been accomplished from linear precursors by reductive amination, 12, 13 and lactam 
formation. 14 Ring expansion of N-protected-4-piperidones by azido-Schmidt reactions with 
2-hyroxyalkyl azides has given N-substituted diazepinones.3 1,4-Diazepin-5-ones have been 
recently made by acid-catalyzed hydrolysis of azeto[I,2-a]imidazoles. 15 In addition, a 
combinatorial library of 1,4-diazepinone derivatives was synthesized by a solid-phase 
approach. 16 
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Figure 2.1 Representative 1,4-diazepin-2-one and pyrrolo-diazepinone systems and related 
biologically active structures. 
Syntheses of the pyrrolobenzadiazepine structures were reviewed in a recent Note on 
pyrroloaryldiazepine construction by modification of the four-component Ugi 
condensation. l7 To the best of our knowledge, only one synthesis of the parent 
pyrrolodiazepinone has been described featuring a Paal-Knorr condensation 1 lactam 
cyc1ization sequence to forrn sequentially the pyrrole and diazepinone rings. lB 
Their remarkable biological activity has inspired development of new synthetic 
methodology for making diazepinone and fused aryl and hetero-aryldiazepinone structures. 
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Present methods employ expensive starting materials, often give low to moderate yields, 
and provide compounds of limited diversity. Employing inexpensive amino acids as chiral 
educts, efficient synthetic approaches for making diazepinone and pyrrolodiazepinone 
heterocyc1es were conceived that use a common homoallylic ketone 94. Four diazepinones 
95 and eight pyrrolodiazepinones 98 and 99 (Schemes and Tables 2.1 and 2.2) were 
synthesized starting from combinations of Ala, Phe, ~-Ala and ~-homophenylalanine to 
provide a-aminoacyl ~-amino esters 93. Homoallylic ketones 94 were then made by Cu-
catalyzed cascade addition ofvinyl Grignard reagent to esters 93. 19 
2.3 ResuUs and Discussion 
a-Aminoacyl ~-amino esters 93 were synthesized by coupling ~-amino esters 91 to the 
respective N-Boc-a-amino acids 92 using TBTU and HOBt in DCM (Scheme 2.1).20 
Dipeptides 93 were isolated by chromatography on silica gel in 85-92% yields. 
Homoallylic ketones 94 were synthesized by treating a-aminoacyl-~-amino esters 93 with 
an excess of freshly prepared vinyl magne sium bromide (600 mol %) in the presence of 
copper cyanide (30-40 mol%) in THF at -78 Oc to rt. 19 After quenching the Grignard 
reaction at 0 oC, work up and solvent removal un der vacuum, homoallylic ketones 94a-c 
were isolated by chromatography on silica gel in yields of 60-75% (Table 2.1). Isolation of 
ketone 94d was best accompli shed by chromatography over silica gel impregnated with 
silver nitrate, in 45% yield.21 
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Scheme 2.1 Synthesis ofDiazepinones 95. 
entry RI R2 93 (%) 94 (%) 95 (%) 
a CH3 H 85 75 45 
b CH2Ph H 90 60 40 
C CH3 CH2Ph 90 65 50 
d CH2Ph CH2Ph 92 45 50 
Table 2.1 Yields of isolated product in the synthesis of 95. 
35 
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Figure 2.2 X-ray diffraction structures of compounds 95c (upper) and 95d (lower). 
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Diazepinones 95 were synthesized from homoallylic ketones 94 by a route featuring 
nitrogen deprotection with TF AlDCM (1: 1), treatment of the trifluoroacetate salt with 
triethyl amine at 0 Oc and reduction of the imine intermediate with sodium 
triacetoxyborohydride in di lute DCM?2 The progress of the imine reduction was followed 
by LCMS analysis, which showed only one diastereoisomer in the crude product as 
confirmed by lH NMR spectroscopy. After work up, diazepinone 95a was isolated after 
this sequence from 94a in 45% yield by preparative HPLC. Diazepinones 95b-d were 
purified by precipitation as hydrochoride salts and isolated in 40-50% overall yields from 
ketones 94b-d (Scheme 1, Table 1). 
The hydrochloride salts of diazepinone 95c and 95d were recrystallized from methanol in 
ethyl acetate to fumish crystals for X-ray analysis. The newly formed stereocentie at the 5-
position of diazepinones 95 was found to have a cis relationship with respect to the 3-
position substituent as expected based on the literature precedent in which reduction of the 
cyclic iminium intermediate occurred with hydride attack on the face opposite the ring 
substituents,16,23 A survey of the Cambridge structural database indicated that the X-ray 
structures of 95c and 95d represent the first 1,4-diazepin-2-one examples. Upon 
comparison of the dihedral angle geometry of the a-amino acid portion of diazepinones 95c 
(0/ 70, ~ -80) and 95d (0/ = 67, ~ = -83) with ideal values of tum conformations, we 
noted the close resemblance to the dihedral angle geometry of the central residue in a 
reverse y-tum conformation (0/ = 60-70, ~ = -70-85; Figure 2.2). 24 
Pyrrolodiazepinones 98 and 99 were made next from the common homoallylic ketone 
intermediate 94. First, 4-ketoaldehydes 96 and 1,4-diketones 97 were obtained from 
Chapter 2 38 
oxidation of olefin 94 using either ozonolysis or periodate/osmium tetraoxide, and by Tsuji-
Wacker oxidation, respectively (Scheme 2.2). 
o R2 0 
RI0~~ 
Boc~ 94 
0 3, DCM, Me2S, 
NaHC03, -78 oC to rt 
o R2 0 
O2, PdC12, CuCl 
7:1 DMFIH20 
o R2 0 
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Scheme 2.2 Synthesis of Pyrrolodiazepinones 98 and 99. 
entry RI R2 96 (%) 97 (%) 98 (%) 99 (%) 
a CH3 H 85 85 30 65 
b CH2Ph H 85 80 40 45 
C CH3 CH2Ph 80 80 55 50 
d CH2Ph CH2Ph 85 80 60 50 
Table 2.2 Yields ofisolated product in the synthesis of98 and 99. 
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4-Keto aldehydes 96 were isolated in 80-85% yields by chromatographie purification after 
ozonolysis of homoallylic ketones 94 in CHzClz lMeOH (1: 1) at -78 oC, and treatment with 
excess dimethylsulfide in the presence of NaHC03?5 Altematively, oxidative c1eavage of 
the double bond of homoallylic ketones 94 was performed with sodium periodiate in the 
presence of catalytic amounts of OSOl6 to afford aldehydes 96 in 65-85% yield after 
chromatography. Comparing the two methods for making aldehyde 96, the ozonolysis was 
found to be more advantageous, because crude product was obtained in suitable purity for 
the subsequent Paal-Knorr reaction. 
l,4-Diketones 97 were produced by Tsuji-Wacker oxidationZ7 employing PdClz (0.2 
equiv.) and CuCI (2 equiv.), in DMF:HzO (9:1) at room temperature under an atmosphere 
of oxygen. After work up and chromatography on silica gel, 1,4-diketones 97 were isolated 
in 80-85% yields (Scheme 2, Table 2). Yields were improved for olefins 94c and 94d by 
using more PdClz (40 mol%) and 2 eq of CuCI in THFlHzO (4:1) at room temperature 
under oxygen atmosphere and agitation in a sonicator. 
Diazepinones 95 and pyrrolodiazepinones 98 and 99 were respectively prepared from 4-
ketoaldehydes 96 and l,4-diketones 97 by a generally effective albeit moderate yielding 
route featuring nitrogen deprotection and Paal-Knorr condensation.Z8 Acid induced Boe 
group removal was accomplished using either HCI gas or TFA in CHzClz, with better 
success on ketoaldehyde 96 using TF A instead of the HCI conditions. Paal-Knorr 
cyc1ization occurred on treatment with triethyl amine and a catalytic amount of toluene 
sulfonic acid in di lute DCM at 0 oC. After quenching with saturated NaHC03 solution, 
pyrrolodiazepinones 99 were isolated by chromatography on silica gel in 45-65% overall 
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yield from 97. An improved Paal-Knorr condensation was then developed using basic 
Amberlyste A-21 ion exchange resin for generating the free amine after Boc deprotection 
with TF A in DCM.29 
Oy~~ 
t-N).·'" "lN~ ~N 0 
H 
Figure 2.3 Dimer 100. 
The use of higher concentrations of ketoaldehydes 96 and diketones 97 in the Paal-Knorr 
annulation to form pyrrolodiazepinone 98 and 99 provided mixtures of monomer and dîmer 
as observed by LCMS analyses. Dimer 100 was isolated by preparative HPLC and 
identified by its doubling in mass, yet relatively simple IH and l3C NMR spectra due to C2 
symmetry (Figure 2.3). 
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2.4 Conclusions 
Practical, diversity-oriented methodology for the synthesis of diazepinone structures has 
been developed that features treatment of a-aminoacyl ~-amino-esters 93 with excess vinyl 
Grignard reagent to yield a common homoallylic ketone intermediate. 
Diazepinones 95a-d, pyrrolo- and methylpyrrolodiazepinones 98a-d and 99a-d, all were 
made in 4 to 6 steps and 16 to 31 % overall yields from inexpensive amino acid building 
blocks 91 and 92. Considering the tolerance of the Cu-catalyzed cascade additions of vinyl 
19 
Grignard reagent to a variety of N-(acyl)amino esters possessing different side-chains, a 
wealth of peptide-based diazepinone and pyrrolo-diazepinone structures may now be 
obtained by this practical approach. 
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crystallographic data Of Sc and Sd. This material is available free of charge via the Internet 
at http://pubs.acs.org 
2.7 Experimental Section 
For reactions performed under anhydrous conditions, glassware was either oyen or flame-
dried and the reaction was performed under a positive pressure of argon. Column 
chromatography was performed on silica gel (Silicycle; 230-400 mesh) and thin layer 
chromatography (TLC) was performed on aluminum plates coated with (O.2mm) silica gel 
F254 from EMD Inc or Silicyle Inc, using the solvent system indicated for TLC. Amino 
acids were obtained from Sigma Aldrich Inc or A vocado Research Chemicals Inc, and were 
N-protected using standard procedures.30 ~-Phenylalanine was prepared according to the 
literature protocol31 and esterified using methanol and acetyl chloride to afford the methyl 
ester.32 
Semi-preparative reverse-phase high performance liquid chromatography (RP-HPLC) was 
carried out on RP-18 column 5J.lm (250 x 20 mm; TARGA column), at a flow rate of 10 
mL/min. The solvent system used in RP-HPLC included the following: solvent A, 0.1 % 
(v/v) TFA in CH3CN; solvent B, 0.1% (v/v) TFA in H20, detector was monitored at 214 
nm. Spectral data were collected on Bruker A V300 (300 MHz) and AV 400 (400 MHz) 
instruments. Chemicals shifts (OH) were reported in parts per million (ppm) and are 
referenced to the residual solvent peak CDCh (7.26 ppm), unless noted otherwise. \3C were 
reported in ppm and were referenced to the residual solvent peak, CDCh (77 ppm) unless 
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noted otherwise. Coupling constants J are reported in Hz. Melting points were deterrnined 
with a capillary meIting point apparatus and are uncorrected. High Resolution Mass 
Spectrometry HRMS, Electro Spray Ionisation (ESI), was perforrned by the Université de 
Montréal Mass Spectrometry Facility. The reported yields are the actual isolated yields of 
purified material and are not optimized. 
General Procedure (1) for the Synthesis of Dipeptides 93a-d 
Triethyl amine (TEA, 3 equiv.) was added over a period of 5 minutes to a suspension of 
beta amino methyl ester hydrochloride salt (1 equiv.) at 0 oC in DCM 1 DMF (9:1, c = 0.1 
M). The mixture was stirred for 30 minutes, treated with N-(Boc)-amino acid (1 equiv.), 
TBTU (1.5 equiv.), and HOBt (1 equiv.), and stirring was continued ovemight. Solvent was 
evaporated under vaccum, water was added to the residue, and the layers were separated. 
The aqueous phase was extracted with DCM (3x 50 mL). The combined organic layers 
were washed with 10% HCI, saturated sodium bicarbonate solution, water and brine, dried 
over magnesium sulphate, filtered and concentrated under vacuum. The residue was 
purified by column chromatography as specified. 
(2S)-Methyl N-(Boc)alaninyl-l3-alaninate (93a): 
The residue was purified on silica gel using the system solvent 4:6 EtOAclhexane. 
Evaporation of the collected fractions gave 93a as a white solid (2.22 g, 90%), mp 76-77 
oC. TLC Rf 0.12 (4:6 EtOAclhexane). lH NMR (400 MHz, CDCh) 0 1.30-1.31 (d, 3H, J= 
7.1), 1.4 (s, 9H), 2.51 (t, 3H, J = 6.2), 3.43-3.65 (m, 2H), 4.11 (br s, IH), 5.27-5.29 (br d, 
1H), 6.9 (br s, IH). BC NMR (100 MHz, CDCh), 0 173.3,173.1,155.8,80.2,52.1,50.5, 
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35.3, 34.1, 28.7, 18.9. HRMS (El) m/z 297.1420 [M+Na+; calcd for CI2H22N205Na: 
297.1412]. [a]D20 -17.4° (c 0.01, DCM). 
(2S)-Methyl N-(Boc)phenylalaninyl-~-alaninate (93b): 
The residue was purified on silica gel using 2:8 EtOAclhexane to afford 93b (2.12 g, yield 
85%) as a white solid, mp 84-85 oC, Rf 0.24 (4:6 EtOAclhexane). IH NMR (400 MHz, 
CDCh) Ù 1.42 (s, 9H), 2.3-2.52 (m, 2H), 2.96-3.14 (m, 2H), 3.29-3.57 (m, 2H), 3.65 (s, 
3H), 4.3 (m, IH), 5.13 (br d, IH), 6.33(br s,IH), 7.19-7.31 (m, 5H). l3C NMR (100 MHz, 
CDCh) Ù 172.9, 172.8, 171.6, 155.8, 137.1, 129.7, 129.0, 127.3, 80.4, 56.3, 52.1, 39.2, 
35.1,34.0,28.7. HRMS (El) mlz 373.1722 [M+Na+; calcd for Ct8H26N205Na: 373.1734]. 
[a]D20 _4.9° (c 0.008, DMF). 
(2S, 2'S)-Methyl N-(Boc)alaninyl-~-hoIDophenylalaninate (93c): 
The residue was purified on silica gel using 4:6 EtOAclhexane to afford 93c (2.14 g, 90% 
yie1d) as a white solid, mp 126-127 oC, Rf 0.25 (4:6 EtOAclhexane), tH NMR (300 MHz, 
CDCh) ù 1.33 (d, 3H, J = 6), 1.5 (s, 9H), 2.55 (t, 2H, J 6),2.84-3.03 (m, 2H), 3.73 (s, 
3H), 4.14 (br ID, IH), 4.50-4.52 (br m, IH), 5.00 (br s, IH), 6.75 (d, IH, J= 9), 7.22-7.37 
(m,5H). 13C NMR (100 MHz, CDCh), Ù 172.9, 172.8, 156.1, 138.3, 130.1, 129.4, 127.6, 
80.9, 52.6, 48.1, 40.7, 37.7, 29.2, 19.3. HRMS (EI) mlz 387.1890 [M+Na+; calcd for 
C19H28N205Na: 387.1890]. [a]D20 -42.3° (c 0.01, DCM). 
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(2S, 2'S)-Methyl N-(Boc)phenylalaninyl-~-homophenylalaninate 93d: 
The residue was purified on silica gel using 2:8 EtOAc/hexane to afford 93d (2.65 g, 5,88 
mmol) 92% yield as a white solid, mp 119-120 oC, Rf 0.11 (2:8 EtOAc/hexane). I H NMR 
(400 MHz, CDCh ), ô 1.43 (s, 9H), 2.29-2.34 (m, 2H), 2.72-2.90 (m, 2H), 2.97- 3.04 (m, 
2H), 3.73 (s, 3H), 4.29-4.3 (br m, IH), 4.41-4.43 (br m, IH), 5.08 (br s, IH), 6.49-6.51 (br 
d, IH), 7.12-7.30 (m, 10H). \3C NMR (100 MHz, CDCh), 172.2, 170.8, 155.6, 137.8, 
137.2, 129.7, 129.6, 129.0, 127.7, 127.3, 127.1, 80.4, 56.4, 52.1, 47.4, 40.1, 39.1, 37.8, 
28.7. HRMS (El) m/z 463.2198 [M+Na+; ca1cd for C2sH32N20sNa: 463.2203]. [a]D20 _4.8° 
(c 0.008, DCM). 
General Procedure (2) for the Synthesis of Homoallylic Ketones 94a-d 
A suspension ofCuCN (0.3 equiv.) in THF (2mL THF per 1 mmol ofCuCN) was cooled to 
-78 oC, treated dropwise with a vinyl magne sium bromide solution in THF (6 equiv. c = 1 
Min THF) over 10 min, followed by a solution ofmethyl ester 93 (1 equiv.) in THF (2 mL 
THF per 1 mmol of 93). The resultant mixture was allowed to stir over night during which 
time the bath warmed to room temperature. The reaction mixture was cooled to 0 oC, 
treated with a IN HCI aqueous solution, and shaken vigorously for 20 minutes. The layers 
were separated, and the aqueous phase was extracted with Et20 (3 x 50 mL). The combined 
extracts were washed with an aqueous solution of saturated sodium bicarbonate (50 mL), 
pH 6.8 phosphate buffer (50 mL) and brine (2 x 50 mL), dried over magne sium sulfate and 
concentrated under vacuum. The residue was then purified by column chromatogrophy as 
specified to provide homoallylic ketone 94. 
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(2S)-N-(Boc)Alanine N'-1-(3-oxohept-6-enyl)amide 94a: 
(The residue was purified on silica gel using 3:2 EtOAc/hexane as eluent to afford olefin 
94a as a white solid (816 mg, 75%): mp 53-55 oC; TLC Rf 0.1 (3:2 EtOAc/hexane); 
IH NMR (400 MHz, CDCh) ô 1.34 (d, 3 H, J= 5.1),1.44 (s, 9 H), 2.29-2.35 (m, 2 H), 
2.49-2.54 (m, 2 H), 2.67 (t, 2 H, J = 5.8), 3.45-3.52 (m, 2 H), 4.09 (br m, 1 H), 4.96-5.32 
(m, 3 H), 5.73-5.85 (m, 1 H), 6.7 (br s, 1H); l3C NMR (100 MHz, CDCh), Ô 209.9, 173.2, 
155.7,137.2,115.9,80.4,50.7,42.4,42.3,34.4,28.7,28.0,19.1. HRMS (El) m/z 321.1776 
(2S)-N-(Boc)Phenylalanine N'-1-(3-oxohept-6-enyl)amide 94b: 
The residue was purified on silica gel using 4:6 EtOAc/hexane as eluent. The evaporation 
of the collected fractions afforded olefin 94b (750 mg, 70% yield) as a white solid: mp 103-
104 oC, Rf 0.24 (4:6 EtOAc/hexane). I H NMR (400 MHz, CDCh) Ô 1.42 (s, 9H), 2.30 (br 
q,2 H), 2.41-2.44 (m, 4 H), 3.03 (m, 2 H), 3.40 (m, 2 H), 4.27 (br s, 1 H), 5.03 (m, 3 H), 
5.7 (m, 1 H), 6.29 (s, 1 H), 7.18-7.31 (m, 5 H). l3C NMR (100 MHz, CDCh), Ô 209.6, 
171.4,155.6,137.2,137.1,129.9,129.7,129.0,127.3,115.9, 80.5, 56.3, 42.2, 39.2, 34.2, 
. + w 28.7,27.9. HRMS (El) m/z 397.2104 [M+Na ; calcd for C21H30N204Na: 397.2098]. [a]D -
6.2° (c 0.008, DMF). 
(2S, l' S)-N-(Boc )Alanine N'-1-(1-benzyl-3-oxohept-6-enyl)amide 94c: 
The residue was purified on silica gel using 4:6 EtOAc/hexane as eluent. Evaporation ofthe 
collected fractions afforded 94c (664 mg, 60% yield) as a yellow white solid: mp 106-109 
oC; Rf 0.28 (4:6 EtOAc/hexane); I H NMR (400 MHz, CDCh) Ô 1.26 (d, 3 H, J= 6.9), 1.45 
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(s, 9 H), 2.3 (br s, 2 H), 2.42-2.47 (m, 2 H), 2.59-2.62 (m, 2 H,), 2.82-2.98 (m, 2 H), 4.07 
(br s, 1 H), 4.42-4.44 (m, 1 H), 4.96-5.03 (m, 3 H), 5.73-5.78 (m, 1 H), 6.79-6.80 (br m, 1 
H), 7.17-7.30 (m, 5 H); l3C NMR (100 MHz, CDCh), 208.9, 171.7, 154.9, 137.5, 136.4, 
128.9, 128.2, 126.3, 115.1, 79.6, 49.9, 46.9, 44.2, 41.9, 39.3, 27.9, 27.1, 18.1. HRMS (El) 
m/z 411.2254 [M+Na+; calcd for C22H32N204Na: 411.2242]. [a]n20 -21.2° (c 0.005, DCM). 
(28, l' S)-N-(Boc )Phenylalanine N'-1-(1-benzyl-3-oxohept-6-enyl)amide 94d: 
The residue was purified over silica gel, that was pretreated dropwise and shaken with an 
aqueous silver nitrate solution (c = 3 M, Ig AgN03 per 10 g of silica) and oven-dried 
ovemight, using 2:8 EtOAclDCM as eluent. Evaporation of the collected fractions afforded 
94d (750 mg, 45% yield) as a white solid: mp 148-150 oC; RfO.l3 (3:7 EtOAc/hexane). IH 
NMR (400 MHz, CDCh) cS 1.43 (s, 9 H), 2.24-2.2.27 (m, 2 H), 2.31-2.37 (m, 4 H), 2.77-
2.86 (m, 2 H), 2.96-2.98 (m, 2 H), 4.27-4.38 (br m, 2 H), 4.99-5.04 (m, 3 H), 5.77-5.79 (m, 
1 H), 6.52-6.55 (br d, 1 H), 7.08-7.29 (m, 10 H). l3C NMR (100 MHz, CDCh), 208.7, 
170.0, 154.8, 137.4, 136.4, 136.1, 128.9, 128.8, 128.7, 128.2, 126.5, 126.3, 114.9,79.7, 
55.6, 46.6, 43.6, 41.8, 39.1, 38.3, 27.9, 27.0. HRMS (El) m/z 465.2748 [M+W; calcd for 
C2sH37N204: 465.2730]. [a]n20 -26.9° (c 0.005, DCM). 
General Procedure (3) for the Synthesis of 1,4-Diazepinones 95a-d 
Homoallylic ketone 94 (1 equiv.) was stirred in a 1:1 TFA/ DCM solution for 30 minutes. 
After removal of the volatiles under vacuum, the residue was placed for 1 hour under 
vacum (5 mm Hg) to remove excess TFA. The residue was dissolved in DCM (c = 10-3 M), 
cooled to 0 oC, treated with triethylamine (1.1 mmol), stirred for 20 minutes, treated with 4 
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A molecular sieves, stirred 15 minutes, treated with sodium triacetoxyborohydride (2 to 3 
equiv.) in two portions and stirred for 3 to 5 days at room temperature under an argon 
atmosphere. The mixture was filtered and the filtrate concentrated on a rotary evaporator. 
The resulting residue was then partitioned between saturated aqueous NaHC03 solution and 
EtOAc. The aqueous layer was separated and extracted with ethyl acetate (3x lOmL). The 
combined organic phase were dried over magnesium sulphate, filtered and evaporated to a 
residue that was purified further as specified. 
(3S, 5S)-5-(But-3-enyl)-3-methyl-l,4-diazepin-2-one 95a : 
The residue was purified by reverse-phase HPLC to afford diazepinone 95a as colorless oil 
(28 mg, 45% yield): Rf 0.24 (5% MeOWCHCh). IH NMR (300 MHz, MeOD) li 1.47 (d, 3 
H, J = 6.9), 1.61 (m, 2 H), 2.0 (m, 2 H), 2.22 (m, 2 H), 3.30-3.32 (m, 2 H), 3.47-3.52 (m, 2 
H), 4.31 (q, 1 H, J = 6.6), 5.08 (m, 2 H), 5.82 (m, 1 H). 13C NMR (75 MHz, CDCh), li 
170.4, 136.7, 115.6, 61.9, 54.6, 48.8, 38.8, 33.0, 29.3, 14.4. HRMS (EI) m/z 205.1311 
[M+Na+; calcd for CIOHI8N20Na: 205.1313]. [a]D20 3.90 (c 0.007, MeOH). 
(3S, 5S)-3-Benzyl-5-(but-3-enyl)-1,4-diazepin-2-one 95b: 
The residue was purified on silica gel using 5% isopropanol in chloroform as eluent. After 
evaporation of the combined collected fractions, the residue was dissolved in ether and 
precipitated as its hydrochloride salt by bubbling of HCI gas to afford diazepinone 95b (14 
mg, 40% yield): mp 138-140 oC; Rj0.32 (5% MeOWDCM). IH NMR (400 MHz, MeOD) 
li 1.60-1.68 (m, 2 H), 2.04-2.30 (m, 4 H), 3.23-3.26 (br m, 1 H), 3.33-3.35 (s, 2 H), 3.42-
3.48 (m, 1 H), 3.50-3.71 (m, 2 H), 4.50-4.53 (m, 2 H), 4.92- 5.16 (m, 2 H), 5.84-5.90 (m, 1 
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H), 7.21-7Al (m,5 H). 13C NMR (100 MHz, CDCh), Ô 167.9,135.9,135.5,128.8,127.7, 
126.3, 114.9, 61.4, 58.3, 37.8, 34.1, 32.3, 31.3, 28.6. HRMS (El) m/z 259.1808 [M+H+; 
calcd for C16H23N20: 259.1804]. [a]n20 -35.60 (c 0.008, DMF). 
(3S, 5R, 7 R)-7-Benzyl-S-(but-3-enyl)-3-methyl-l,4-diazepin-2-one 9Sc : 
The residue was purified on silica gel using 5% isopropanol in chloroform as eluent. After 
evaporation of the combined coUected fractions, the residue was dissolved in ether and 
precipitated as a hydrochloride salt by bubbling of HCI gas. The hydrochloride salt was 
recrystallized from a mixture of methanol and ethyl acetate to afford diazepinone 9Sc (16 
mg, 50% yield) as a white solid: mp 264-266 oC; Rf 0.2 (3% methanol in DCM). lH NMR 
(300 MHz, MeOD) Ô 1.15-1.20 (m, 2 H), 1.45-1.47 (d, 3 H, J = 5.6), 1.56 (br m, 1 H), 
1.94-1.98 (m, 2 H), 2.15-2.19 (m, 2 H), 2.8-3.32 (m, 2 H), 3A2-3.50 (m, 2 H), 3.98-4.00 
(m, 1 H), 4.35-4.37 (m, 1 H), 4.75-4.8 (m, 1 H), 5.68-5.73 (m, 1 H), 7.27-7.35 (m, 5 H). 
l3C NMR (75 MHz, CDCh), 170A, 138.5, 137.2, 130.5, 129.9, 128.1, 116.9, 62.0, 55.6, 
53.2,41.7, 37.3, 33.6, 30.3, 15A. HRMS (El) m/z 273.1951 [M+H+; calcd for C17H25N20: 
273.1961]. [a]n20 -35.30 (c 0.003, MeOH). The X-ray structure of Sc was soived by direct 
methods using SHELXS-97, refinement was performed using SHELXL-97: (C17H25N20Cl) 
Mr = 308.84, orthorombique, space group P212121, a 5.3977 (6) A, b = 12.8158 (13) A, c 
= 24.189 (3) A, v= 1673.3 (3) A3, Z = 4; Pcalcd= 1.226 g.cm-3, Il = 2.016 mm-l, T= 150 
(2) K, F(O,O,O) = 664 , Omax = 59.020 ; 15250 measured reflections, 2356 independent 
reflections and 1785 reflections with [1> 20' (1)] RI = 0.0429, roR2 = 0.1067,R int 0.081. 
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(3S, 5R, 7R)- 5-Butyl-3,7-diphenyl-[1,4]diazepin-2-one 95d. 
The residue was purified on silica gel using 5% isopropanol in chloroforrn as eluent. After 
evaporation of the combined collected fractions, the residue was dissolved in ether and 
precipitated as a hydrochloride salt by bubbling of HCI gas. The hydrochloride salt was 
recrystallized from a mixture of methanol and ethyl acetate to afford diazepinone 95d (9 
mg, 50% yield) as a white solid: mp 175 .. 177 oC; R.r 0.4 (5% MeOHlDCM). I H 'NMR (400 
MHz, MeOD) 81.40-1.50 (m, 2H), 1.98-2.22 (m, 4H), 2.76 (q, IH ,J = 9.1), 3.0-
3.34(m,2H), 3.43-3.52 (m, 2H), 4.03-4.11 (m, IH), 4.52-4.55 (m, IH), 4.78-4.90 (m, 2H), 
5.80-5.7 (m, IH), 7.2-7.4 (m, lOH). l3C NMR (100 MHz, CDCh), 167.0, 136.7, 135.4, 
135.3, 128.9, 128.7, 128.1, 127.7, 126.3, 126.2, 115.2, 60.5, 58.2, 51.1, 39.8, 35.5, 34.1, 
31.8, 28.6. HRMS (El) m/z 349.2274 [M+W; ca1cd for C23H29N20: 349.2278]. [a]ozo -
45.5° (c 0.007, MeOH). 
The X-ray structure of 95d was solved by direct methods using SHELXS-97, refinement 
was perforrned using SHELXL-97: (Cz3Hz9NzOCI (CH30H)) Mr = 400.95, Monoc1inic, 
space group C2, a = 24.254 (6) A, b = 6.643 (13) A, c = 17.061 (3) A, v= 2251.4 (7) A3, Z 
= 4; P calcd = 1.183 g.cm-3, ~ = 1.630 mm-l, T = 100 (2) K, F(O,O,O) = 664 , Bmax = 68.25° ; 
14342 measured reflections, 3404 independent reflections and 2178 reflections with [1> 20' 
(1)] RI = 0.0429, roRz = 0.2786,R in! = 0.106. 
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General Procedure (4) for the Synthesis of Ketoaldehydes 96a-d 
Procedure 4a : 
To a solution of homoallylic ketone 94 (1 equiv.) in a 3:1 dioxane/water solution, 2,6-
lutidine (2 equiv.), OS04 (2.5 mol% in 2-methyl-2-propanol, 0.02 equiv., c 0.1 M) and 
NaI04 (6 equiv.) were added and the reaction was stirred at room temperature for 3 hours. 
After complete consumption of starting olefin 94 was observed by TLC, water (18 mL) and 
DCM (36 mL) were added to the mixture and the organic layer was separated. The 
aqueous layer was extracted with DCM (3x 25 mL). The combined organic layers were 
washed with brine (2x 25mL) and dried over magnesium sulphate. The volatiles were 
removed under vacuum and the residue was purified by silica gel column chromatography 
as specified. 
Procedure 4b: 
A solution ofhomoallylic ketone 94 (1 equiv.) in a 1:1 MeOHIDCM solution (c;:;; 0.04 M) 
was cooled to -78 oC and treated with ozone until a blue colored solution persisted. The 
reaction mixture was purged at -78 oC with a stream of argon to remove excess ozone, 
treated with dimethyl sulfide (6 equiv.) and solid sodium bicarbonate (8 equiv.), stirred 
overnight, after which time the bath temperature had warmed to room temperature. 
Removal of solvent by rotary evaporation gave a crude product that was sufficiently pure 
for the next step. 
(2S)-N-(Boc)Alanine N'-1-(3,7-dioxoheptanyl)amide 96a : 
The residue was purified by silica gel column chromatography using 8:2 EtOAclhexane as 
eluent to afford keto aldehyde 96a (905 mg, yield 85%) as a brown oil: Rf 0.3 (8:2 
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EtOAelhexane); lH NMR (400 MHz, CDCh) Ô 1.32 (d, 3 H), 1.42 (s, 9 H), 2.71 (br t, 4 H), 
2.77 (m, 2 H), 3.50 (d, 2 H, J= 5.92), 4.04-4.14 (m, 1 H), 5.14 (s, 1 H), 6.7 (s, 1 H), 9.77 
(s, 1 H). l3C NMR (100 MHz, CD Ch), Ô 207.7, 200.7,172.5,155.0,79.5,49.80,41.6,37.1, 
34.4, 33.9, 27.9, 18.3. HRMS (El) mlz 323.1577 [M+Na+; ealcd for Cl4H24N205Na+ 
323.1574]. [a]n20 -11.9° (c 0.01, DCM) 
(2S)-N-(Boc )Phenylalanine N' -1-(3,7 -dioxoheptanyl)amide 96b: 
The erude produet was purified on siliea gel using the solvent system 7:3 EtOAelhexane to 
afford keto aldehyde 96b (854 mg, 85% yield) as a white solid: mp 106-107 oC, Rf 0.11 (7:3 
EtOAelhexane). lH NMR (400 MHz, CDCh) Ô 1.40 (s, 9 H), 2.62-2.76 (m, 4 H), 2.74-2.76 
(br q, 2 H), 3.04 (d, J= 6.6,2 H), 3.41-3.45 (m, 2 H), 4.28 (br d, 1 H), 5.10 (br d, 1 H), 6.33 
(s, 1 H) 7.13-7.30 (m, 5 H), 9.77 (s, 1 H). l3C NMR (100 MHz, CDCh), Ô 207.4, 199.9, 
170.8, 154.9, 136.4, 128.9, 128.2, 126.4, 79.7, 55.5, 41.4, 38.4, 37.1, 34.4, 33.7, 27.9. 
HRMS (El) mlz 399.1890 [M+Na+; ealcd for C2oH28N205Na: 399.1875]. [a]D20 2.8° (c 
0.005, DCM). 
(2S, l' S)-N-(Boc )Alanine N'-I-(I-denzyl-3,7-dioxoheptanyl)amide 96c: 
The crude produet was purified on siliea gel using the solvent system 6:4 EtOAelhexane to 
afford keto aldehyde 96c (80 mg, 80% yield) as a white solid: mp 125-127 oC; Rf 0.19 (6:4 
EtOAelhexane). lH NMR (300 MHz, CDCh) Ô 1.27-1.29 (d, 3 H, J = 6.5), 1.46 (s, 9 H), 
2.66-2.71 (m, 4 H), 2.74-2.87 (m, 2 H), 2.89-2.98 (m, 2 H), 4.1 (br s, 1 H), 4.44-4.47 (br d, 
1 H), 4.99-5.01 (br m, 1 H), 6.72-6.75 (br d, 1 H), 7.2-7.35 (m, 5 H), 9.8 (s, 1 H). l3C NMR 
(75 MHz, CDCh) Ô 208.6, 201.2, 173.0, 156.2, 138.6, 138.6, 130.1, 129.5, 127.6. 80.9, 
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51.2, 48.3, 45.5, 40.5, 38.3, 36.1, 29.2. HRMS (El) mlz 413.2047 [M+Na+; calcd for 
C21H30N205Na: 413.2047]. [a]D20 -49.2° (c 0.005, DCM). 
(2S, l' S)-N-(Boc )Phenylalanine N'-1-(1-benzyl-3,7-dioxoheptanyl)amide 96d: 
The crude product was purified on silica gel using the solvent system 6:4 EtOAc/hexane to 
afford keto aldehyde 96d (85 mg, 85% yield) as a white solid: mp 125-126 oC; Rf 0.2 (4:6 
EtOAclhexane). IH NMR (400 MHz, CDCh ) () 1.42 (s, 9 H), 2.40-2.42 (m, 1 H), 2.54-
2.59 (m, 3 H), 2.70-2.74 (br q, 2 H), 2.77-2.88 (m, 2 H), 3.00 (br m, 2 H), 4.28 (m, 1 H), 
4.40 (m, 1 H), 5.04 (br s, 1 H), 6.49-6.50 (br d, 1 H), 7.12-7.31 (m, 10 H), 9.78 (s, 1 H). DC 
NMR (100 MHz, CDCh), 207.1, 199.8, 170.1, 155.0, 137.3, 136.4, 129.0, 128.8 128.2, 
126.4, 126.3, 79.8, 55.5,46.8,43.7,39.1,38.2,36.9,34.8,28.0. HRMS (El) mlz 489.2365 
[M+Na+; calcd for C27H34N205Na: 489.2370]. [a]D20 -22.8° (c 0.006, DCM) 
General Procedure for the Synthesis of Diketones 97a-d 
Olefin 94 (1 equiv.) was added as a solid with stirring to a mixture of PdCh (2 equiv.) and 
CuCI (0.3 equiv.) in a 7: 1 DMF/water solution (c = 0.375M) under an oxygen atmosphere. 
After complete consumption of olefin 94 was observed (typically 2 days, as monitored by 
TLC), the reaction mixture was treated with 10 mol% of aqueous citric acid solution. The 
layers were separated and the aqueous phase was extracted with EtOAc (3 x 50 mL). The 
combined organic layers were washed with water (100 mL) and brine (2 x 50 mL), dried 
over magnesium sulfate, filtered and concentrated under vacuum. The residue was purified 
by column chromatography as specified. 
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(2S)-N-(Boc)Alanine N'-1-(3,6-dioxoheptyl)amide 97a: 
The residue was purified by column chromatography using 7:3 EtOAc/hexane as eluent. 
Evaporation of the collected fractions gave dione 97a (895 mg, 85% yield) as a white solid: 
mp 83-85 oC; TLC Rf 0.11 (7:3 EtOAc/hexane). IH NMR (400 MHz, CDCh) Ô 1.30-1.32 
(d,3 H, J= 7.2), 1.41 (s, 9 H), 2.16 (s, 3 H), 2.60-2.63 (m, 2 H), 2.68-2.73 (m, 4 H), 3.55 
(q, 2 H:J= 6.0), 4.1 (br s, 1 H), 5.2 (br s, 1 H), 6.7 (s, 1 H). J3C NMR (100 MHz, CD Ch), 
Ô 208.4, 206.9, 172.4, 154.9, 79.4,49.8,41.7,36.7,35.9,33.9,29.4,27.9, 18.3. HRMS (El) 
m/z 337.1734 [M+Na+; ca1cd for ClsH26N20sNa: 337.1727]. 
[a]D20 = 8.0° (c 0.005, DCM). 
(2S)-N-(Boc )Phenylalanine N'-1-(3,6-dioxoheptyl)amide 97b: 
The residue was purified on silica gel using 7:3 EtOAc/hexane as eluent. The evaporation 
of the collected fractions afforded dione 97b (834 mg, 80% yield) as a yellow sol id: mp 
103-104 oC; Rf 0.37 (7:3 EtOAc/hexane). IH NMR (400 MHz, CDCh ) Ô 1.39 (s, 9 H), 
2.17 (s, 3 H), 2.48-3.03 (m, 6 H), 3.02-3.04 (d, 2 H, J = 6.2), 3.41-3.44 (m, 2 H), 4.29-4.30 
(br m, 1 H), 5.16-5.18 (br s, 1 H), 6.40 (s, 1 H), 7.18-7.29 (m, 5 H). J3C NMR (100 MHz, 
CDCh), Ô 208.2, 206.9, 170.7, 155.0, 136.5, 129.0, 128.2, 126.4, 79.6, 55.5, 41.6, 38.4, 
36.7, 35.9, 33.8, 29.4, 27.9. HRMS (El) m/z 413.2047 [M+Na+; calcd for C21H30N20sNa: 
321.1776]. [a]D20 _8.5° (c 0.005, DCM). 
(2S, 1 'S)-N-(Boc)Alanine N'-1-(1-benzyl-3,6-dioxoheptyl)amide 97c : 
The residue was purified on silica gel using 7:3 EtOAc/hexane as eluent. The evaporation 
of the collected fractions afforded dione 97c (833 mg, 80% yield) as a yellow solid: mp 
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125-128 oC; Rf 0.37 (60% EtOAc/hexane). tH NMR (300 MHz, CDCh) 0 1.19 (d, J= 7.0, 
3 H), 1.43 (s, 9 H),1.37 (s, 1 H), 2.12 (s, 3 H), 2.52-2.86 (m, 5 H), (m, 2 H), 4.00 (br s, 1 
H), 4.34-4.38 (m, 1 H), 5.23 (br s, 1 H), 6.65 (br s, 1 H), 7.12-7.25 (m, 5 H). BC NMR (75 
MHz, CDCh), 209.3,208.0, 172.9, 156.0, 138.7, 130.1, 129.4, 127.5,80.6,51.1,48.4,45.4, 
40.7,37.8,37.6,30.7,29.2, 19.4. HRMS (El) m/z 405.2384 [M+H+; calcd for C22H33N205: 
405.2377]. [o.]D20 -41.6° (c 0.005, DCM). 
(2S, l' S)-N-(Boc)Phenylalanine N'-1-(1-benzyl-3,6-dioxoheptyl)amide 97d : 
The residue was purified on silica gel using 7:3 EtOAc/hexane as eluent. The evaporation 
of the collected fractions afforded dione 97d (800 mg, 80% yield) as a yellow white solid: 
mp 138-140 oC; Rj0.11 (4:3 EtOAc/hexane). IH NMR (400 MHz, CDCh) 0 1.42 (s, 9 H), 
2.20 (s, 3 H), 2.35-2.39 (m, 4 H), 2.48-2.52 (m, 2 H), 2.57-2.84 (m, 2 H), 3.00 (br s, 2 H), 
4.28-4.38 (m, 2 H), 5.04 (br s, 1 H), 6.52 (br s, 1 H), 7.13-7.28 (m, 10 H). l3C NMR (100 
MHz, CDCb), 207.9, 206.7, 189.1, 170.0, 154.8, 137.4, 136.5, 129.0, 128.9, 128.2, 126.4, 
126.3, 79.6, 55.6, 46.9, 43.7, 39.1, 38.3, 36.4, 36.3,29.5, 27.9. HRMS (El) m/z 481.2697 
[M+H+; calcd for C2SH37N205: 481.2676]. [o.]D20 -24.2° (c 0.005, DCM) 
General Procedure for the SynthesÎs of Pyrrolodiazepinones 98a-d and 99a-d 
MethodA: 
Ketoaldehyde 96, or diketone 97 (1 equiv.), was treated with a 1:1 TFAI DCM solution for 
30 minutes. The volatiles were removed under vacuum and the residue was placed under 
vacuum (5 mmHg) for 1 hour to remove excess TFA. The residue was dissolved in DCM (c 
5.10-4 M). The mixture was cooled to 0 oC, treated with triethylamine (1.1 equiv.) and 
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stirred for 20 minutes. The ice bath was removed. Toluene sulfonic acid (0.02 mmol) was 
added to the mixture, which was stirred ovemight and then treated with a saturated aqueous 
sodium bicarbonate solution. The layers were separated. The aqueous phase was extracted 
with DCM (3 x IO mL). The combined organic laters were dried over magnesium sulphate, 
filtered and concentrated on a rotary evaporator to a residue that was purified by silica gel 
column chromatography as specified. 
MethodB: 
The preparation of pyrrolodiazepinones 98 and 99 was performed as described above for 
method A, with the exception that after treatment of ketoaldehyde 7 with TF AlDCM for 5 
minutes and evaporation of the excess ofTFA, the residue was dissolved in DCM (c 5 xIO-4 
M) and treated with Amberlyste A-21 (10 to 15 mmol). The pH was monitored using pH 
paper until the solution was pH 6 to 7. After filtration to remove the supported base, the 
mixture was shaken for 3 hours or until the disappearance of the starting material (as 
monitored by TLC). 
(S)-2,3-Dihydro-5-methyl-lH-pyrrolo[1,2-gl [1,4]diazepin-4(5H)-one 98a : 
The residue was purified on silica gel using 2:8 EtOAc/DCM as eluent to afford 
pyrrolodiazepinone 98a (7mg, 30%) as a colorless oil: Rf 0.17 (2:8 EtOAc/DCM). IH 
NMR (400 MHz, acetone-dt;) Ô 1.61 (d, 3H, J = 7.3), 2.52-2.09 (m, 2 H), 3.06-3.07 (m, 1 
H), 3.84-3.89 (m ,1 H), 4.59 (q, 1 H, J = 7.29), 5.62 (br s, 1 H), 5.74-5.75 (m, 1 H), 6.02 (t, 
1 H, J = 3.2), (dd, 1 H, J =1.7). I3C NMR (100 MHz, acetone-d6) Ô 170.8, 129.9, 116.7, 
I08.4, I06.0, 55.1, 36.7, 25.2, 16.6. HRMS (El) mlz 165.I029 [M+H+; calcd for C9H13N20: 
165.I022]. [a]D20 -I06.8° (c 2.5.IO-3, DCM). 
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(S)-5-Benzyl-2,3-dihydro-lH-pyrrolo[1,2-g] [1,4]diazepin-4(5H)-one 98b : 
The residue was purified on silica gel using 3:7 EtOAclhexane as eluent to afford 
pyrrolodiazepinone 98b (10 mg, 40% yield) as a colorless oil: RjO.17 (3:7 EtOAclhexane). 
lH NMR (400 MHz, acetone-d6) 2.1 (s, 2H), 2.15-2.33 (m, 2H), 3.69-3.72 (br d, 2H), 4.61-
4.63 (m, lH), 5.60 (s, IH), 6.0 (s, lH), 6.7 (s, IH), 6.83 (s, 2H), 7.05-7.14 (m, 4H). 13C 
NMR (100 MHz, acetone-~), 170.07, 137.67, l32.9, 128.42, 127.65, 125.92, 117.23, 
108.78, 105.63, 61.0, 41.36, 38.61, 23.69. HRMS (El) m/z 503.2412 [2M+Na+; calcd for 
C30H32N402Na+: 503.2417]. [a]o20 -l32.7° (c 0.008, DCM). 
(2S,5S)-2-Benzyl-2,3-dihydro-5-methyl-lH-pyrrolo[1,2-g][ 1,4]diazepin-4(5H)-one 98c: 
The residue was purified on silica gel using 4:6 EtOAclhexane as eluent to afford 
pyrrolodiazepinone 98c (14 mg, 55%) as a colorless oil: RjO.24 (4:6 EtOAclhexane). lH 
NMR (400 MHz, acetone-~) ô 1.60 (d, 3 H, J= 7.0),1.83-2.92 (m, 4 H), 3.14-3.18 (m, 1 
H), 4.05-4.07 (br m, 1 H), 5.053 (t, IH, J = 6.8), 5.88 (s, 1 H), 5.97 (t, J = 3.2, 1 H), 6.55 
(br s, 1 H), 6.7 (d, J= 1.2, 1 H), 7.28-7.36 (m, 5 H). I3C NMR (100 MHz, acetone-~) Ô 
170.0, l37.5, 129.1, 128.3, 128.2, 126.3, 117.5, 107.7, 106.3, 54.5, 53.8, 41.5, 30.0, 15.8. 
HRMS (El) m/z 255.1498 [M+Na+; ca1cd for C16H19N20: 255.1491]. [a]o20 -17.3° (c 0.007, 
DCM). 
(2S, 5S)-2,5-Dibenzyl-2,3-dihydro-lH-pyrrolo [1,2-gI[1,4] diazep in-4(5H)-one 98d : 
The residue was purified on silica gel using 4:6 EtOAclhexane as eluent to afford 
pyrrolodiazepinone 98b (17 mg, 60%) as an colorless oil Rf 0.4 (4:6 EtOAclhexane). IH 
NMR (400 MHz, acetone-~) Ô 2.89-3.02 (m, 4 H), 3.27-3.31 (m, 2 H), 3.85-3.89 (m, 1 H), 
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5.0 (q, J 3.3, 1H), 5.73-5.74 (m, 1H), 5.77 (s, 1H), 6.28 (br s, IH), 6.55 (s, IH), 6.98-
7.36 (m, 10 H). 13C NMR (100 MHz, acetone-<Î6) Ô 169.4, 137.0, 129.2, 128.8, 128.7, 
128.2,127.7, 126.4, 126.1, 121.1, 107.4, 105.9,64.1,55.6,42.2,39.0,30.1,29.2. HRMS 
(El) m/z 331.1809 [M+Na+; calcd for C22H23N20: 331.1804]. [a]D20 16.40 (c 0.0075, DCM). 
(S)-2,3-Dihydro-5, 7-dimethyl-lH-pyrrolo[1,2-g] [1,4]diazepin-4(5H)-one 99a : 
The residue was purified on silica gel using 2:8 hexane/diethyl ether as eluent to afford 
pyrrolodiazepinone 99a (36 mg, 65% yield) as a white solid: mp 114-116 oC; Rf 0.26 
(diethyl ether). IH NMR (400 MHz, CDCb) Ô 1.65 (d, 3 H, J 7.3),2.23 (s, 3 H), 3-3.2 (m, 
2 H), 3.41-3.53 (m,2H),4.94(q, 1 H,J=7.3), 5.81 (s, 1 H), 5.84 (d, 1 H,J=2.8), 7.25 (br 
s, 1 H). 13C NMR (100 MHz, CDCh) Ô 173.6, 129.9, 128.8, 106.2, 105.7,56.5,43.8,26.5, 
21.3, 12.8. HRMS (El) m/z 179.1789 [M+H+; cal cd for ClOH ISN20: 179.1186]. [a]D20 16.40 
(c 0.001, EtOH). 
(S)-5-Benzyl-7-methyl-2,3-dihydro-1H-pyrrolo[I,2-d] [1,4] diazepin-4-one (99b): 
The residue was purified on silica gel using 20% hexane in ether as eluent to afford 
pyrrolodiazepinone 99b (32 mg, 50% yield) as an oil: Rf 0.16 (1:1 EtOAclhexane). IH 
NMR (400 MHz, CDCh) ô 1.51 (s, 3 H), 3.04-3.22 (br d, 2 H), 3.25-3.53 (m, 4 H), 4.86-4.9 
(m, 1H), 5.6 (s, 1 H), 5.88 (d, 1 H, J = 2.3), 6.84-7.21 (m, 6H). l3C NMR (100 MHz, 
CDCb), ô 171.8,136.3,130.5,129.8,126.1, 128.0,126.7,106.0,105.4,63.3,44.6,41.9, 
26.6, 11.3. HRMS (El) m/z 277.1305 [M+Na+; calcd for C16H18N20Na: 277.1311]. [a]D20 
48.1 0 (c 0.008, DCM). 
Chapter 2 59 
(2S,5S)-2-Benzyl-2,3-dihydro-5, 7 -dimethyl-lH-pyrrolo [1 ,2-g] [1,4] diazepin-4(5H)-one 
99c: 
The residue was purified on silica gel using 2:8 hexane/diethyl ether as eluent to afford 
pyrrolodiazepinone 99c (38 mg, 55% yield) as an oil: Rf 0.38 (diethyl ether). I H NMR (400 
MHz, CDCh) 8 1.65 (d, 3 H, J= 6), 2.22 (s, 3 H), 2.75-2.78 (m, 1 H), 2.78-3.04 (m, 3 H), 
3.75-3.80 (m, 1 H), 4.95 (q, 1 H, J = 7.4), 5.80 (s, 2 H), 5.84-8.85 (d, 1 H, J = 2.7), 7.22-
7.39 (m, 5 H). \3C NMR (100 MHz, CDCh) 8 172.0, 135.6, 128.9, 128.8, 128.5, 128.4, 
127.1,106.0,105.7,56.3,56.0,43.3,32.1,21.4,11.8. HRMS (El) mlz 291.1468 [M+Na+; 
calcd for C17H20N20Na: 291.1459]. [a]D20 59.0° (c 0.017, DCM). 
(2S,5S)-2,5-Dibenzyl-2,3-dihydro-7 -methyl-lH-pyrrolo [1,2-g] [1,4 ]diazepin-4(5H)-one 
99d: 
The residue was purified on silica gel using 4:6 EtOAc/hexane as eluent to afford 
pyrrolodiazepinone 99d (36 mg, 50% yield) as an oil: Rf 0.4 (4:6 EtOAc/hexane). I H NMR 
(400 MHz, CDCh) 8 1.47 (s, 3 H), 2.75-2.80 (m, 2 H), 2.99-3.07 (m, 2 H), 3.28-3.38 (m, 2 
H), 3.78-3.80 (br d, 1 H), 4.86-4.89 (br d, 1 H), 5.60 (s, 1 H), 5.87 (s, 1 H), 5.98 (s, 1 H), 
7.21-7.40 (m, 10 H). l3C NMR (100 MHz, CDCh) 8 171.2, 136.2, 135.5, 130.5, 129.1, 
129.0, 128.8, 128.2, 128.0, 127.1, 126.7, 106.3, 150.4, 62.8, 56.6, 43.3, 41.8, 32.3, 11.2. 
HRMS (El) mlz 345.1961 [M+H+; calcd for C23H2SN20: 345.1967] [a]D20 - 47.7° (c 0.002, 
DCM) 
/\ 
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Macrocycle 100 (dimmer): 
As described for the synthesis of pyrrolodiazepinones 98a-d and 99a-d, with the exception 
that the concentration of solution after Boc removal was 5x 10-2 M. The residue was purified 
by reverse-phase HPLC to afford macrocyc1e 100 as a solid (6 mg, 20% yield), Rf 0.26 
(diethyl ether). lH NMR (400 MHz,CDCh), 1.66 (d, 6H, J= 7.4), 2.2 (s, 6H), 2.38-2.42 (m, 
2H), 2.72 -2.80 (m, 4H), 3.08-3.15 (m, 2H), 4.2-4.27 (m, 2H), 4.74 (q, 2H, J = 7.2), 5.62 (s, 
2H), 5.80 (d, 2H, J =2.7). 13C NMR (100 MHz, CDCh), 170.8, 128.8, 127.2, 106.8, 105.1, 
53.2,35.1,28.1, 15.9, 12.4. 
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3.1 Abstract 
Six 1,3,5-trisubstituted 1,4-diazepin-2-ones were synthesized by a sequence featuring the 
cascade addition of vinyl Grignard to N-[Boc-aminoacyl]-N-alkyl-p-amino esters, followed 
by Boc group removal and annulation by a reductive amination process. Relative to the 
parent sequence employing N-Boc-aminoacyl p-amino esters to make 3,5-disubstituted 
heterocycle, the additional N-alkyl substituent caused a noticeable acceleration and gave 
relatively higher yield in the annulation reaction to provide 1,4-diazepin-2-one. 
3.2 Introduction 
Mimicry of peptide conformations by privileged organic structures has proven effective 
for identifying candidates for drug development. 1 For example, 1,4-diazepin-2-ones have 
been suggested to function as privileged structures in medicinal chemistry,2 because the 
seven-member diazepinone ring may mimic f3- and y-tum secondary structures.3,4 In X-ray 
structural analyses of 1,4-diazepinones,5 the confonnation of the a-amino acid moiety in 
the ring system mimicked the dihedral angle geometry of an ide al reverse y-tum (\jI = 60 to 
70°, $ = -70 to -85°, Figure 3.1).6 y-Tum conformations have been suggested to be 
populated by many biologically active peptides, such as angiotensin II, bradykinin, Leu-
enkephalin, oxytocin and urotensin.7,8 Furthermore, biologically active 1,4-diazepinones 
include antagonists of the lymphocyte function-associated antigen-ll immunoglobulin 
superfamily ICAM-l interaction,9 the liposidomycin family of nucleoside antibiotics that 
inhibit bacterial peptidoglycan synthesis, 10 as weIl as anticonvulsants. 11 The development of 
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methodology for the synthesis of 1,4-diazepin-2-ones is thus weIl merited with potential for 
creating new biologically active peptide mimics. 
HN> O~NH 
1,4-Diazepin-2-one 
'Y.Turn 1,3,5-Trisbstituted-I ,4-diazepin-2-one 
Figure 3.1 Structural relationship between y-tum and 1,4-diazepin-2-ones. 
The diazepinone ring bas been typically formed from linear precursors by intramolecular 
reductive amination,12 lactam formation,I3,14 and transamidation reactions. 15 For example, 
employing a reductive amination reaction, a library of 1,4-diazepinones was generated by a 
solid-phase approach. 16 A sequence employing Ugi multicomponent and Mitsunobu 
annulation reactions has also delivered libraries of 1,4-diazepin-1- and -5-ones. 17 
We recently reported a general method for the synthesis of enantiopure 3,5-disubstituted 
1,4-diazepin-2-ones from inexpensive amino acids.5 This process involved the cascade 
addition of vinyl magnesium bromide to an a-aminoacyl ~-amino ester to provide a y,8-
unsaturated ketone intermediate. 18 Nitrogen deprotection and intramolecular reductive 
amination provided the 1 ,4-diazepinone. 5 
In light of the relationship between 1,4-diazepin-2-ones and y-tum conformations, the 
display of substituents on the 1-, 3- and 5-positions of the heterocycle could respectively 
mimic the pharmacophores at the i, i + 1 and i + 2 residues in the r-tum (Figure 1). 
Methodology for introducing substituents at the 3- and 5-positions was previously achieved 
by the employment of different a-amino acid starting materials and by the modification of 
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the olefin of the y,c5-unsaturated ketone, respectively.5 Employing a-aminoacyl ~-amino 
esters possessing N-alkyl substituents, we have now elaborated our synthesis methodology 
to introduce functionality at the Ni-Position of the 1,4-diazepin-2-one. Moreover, the 
presence of the N-alkyl substituent was noted to accelerate ring c10sure in the reductive 
amination step and improve the yield of diazepinone. 
3.3 ResuUs and Discussion 
a-Aminoacyl ~-amino esters possessing N-alkyl substituents were initially prepared from 
coupling of N-Boc-a-amino acids to N-alkyl ~-amino esters. Methyl N-alkyl ~­
aminopropionate derivatives 102a-d were synthesized by reductive amination of the imine 
generated from methyl fJ-alaninate 101 and the respective aldehyde 101" with sodium 
triacetoxy borohydride and 1 % acetic acid in DMF.'9 N-Alkyl ~-amino esters 102a-d were 
isolated from the reductive amination procedure in 70-93% yield after purification by 
chromatography on silica gel (Scheme 1). The requisite aldehydes were usually obtained 
from commercial sources. Benzylthioacetaldehyde was prepared by oxidation of 2-
benzylthioethanol using Cr03epyridine?O Altematively, benzyl and phenylthioacetaldehydes 
were prepared by alkylation of the respective thiol with 3-bromo-l, I-dimethoxyethane, 
followed by acetal hydrolysis using 2N HCI at 80 Oc for 24 h?' 2,4-Dimethoxy- and 4-
benzyloxybenzyl amino esters 102a and 102b exhibited identical spectral data as 
previously described?2, 23 
Dipeptides 103a-d and 104a,b were respectively prepared by coupling either Boc-Phe or 
a-Boc-(E-Cbz)-Lys to secondary amino esters 2 using HATU in DMF,24 and isolated by 
silica gel chromatography in 55-90% yield. Lysine was employed as the a-amino acid, 
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because of the importance of constrained E-ammo alkyl ammo acids,25 as weIl as to 
examine the influence of a remote carbamate group on the synthesis method. Homoallylic 
ketones l05a-d and 106a,b were synthesized in 35-60% yields by respectively treating (1-
aminoacyl ~-amino esters l03a-d and l04a,b with an excess of freshly prepared vinyl 
magnesium bromide in the presence of a catalytic amount of CuCN in THF at -45 oC 
followed by warming to rt. 18 
Diazepinones l07a-d and l08a,b were respectively synthesized from y,O-unsaturated 
ketones l05a-d and l06a,b by removal of the Boe group using al: 1 TF A:DCM solution, 
free-basing of the amine TF A salt using Amberlyste A-21 ion exchange resin,26 and 
reductive amination of the imine intermediate with sodium cyanoborohydride in THF 
(Scheme 3.1). We observed only one diastereoisomer by LCMS for diazepinones l07a,b,d 
and l08a,b; diazepinone l07b was observed to consist of a 30: 1 mixture of 
diastereoisomers. The relative configuration of the newly formed stereocentre m 
diazepinones l07a-d and l08a,b was assigned to have a cis-relationship based on our 
previous studies of 1,4-diazepin-2-ones.5 The cis assignment was confirmed by a NOESY 
experiment in which strong NOE was observed between the C3 and Cs protons of 
diazepinone l07b. 
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C02Me ( RLCHO, NaBH(OAc)3 101" C02Me ( 
NH2HCI 
101 
R2y C02H 
NHBoc 
HATU, Et3N, DMF 
NHCH2R1 
102 
o 
R20N~c02Me 
BocHN l.R1 
103: R2 = Bn 
104 : R2 = (CH2)4NHCbz. 
H2C=CHMgBr (400-600 mol%), ~ 
CuCN (60 mol%), THF 2y( 0 
- 45 oC to rt .. R N 
TFA: DCM (1:1) 
Amberlyst A-21,THF 
NaBH3CN, THF 
a 2,4-(MeOhC6H3-
b 4-(BnO)C6H4-
c BnSCHr 
d PhSCHr 
BocHN l.R1 
105: R2 = Bn 
106 : R2 = (CH2)4NHCbz. 
l-'N~ 
R O~N~ 
R2 
107: R2 = Bn 
108 : R2 = (CH2)4NHCbz. 
Scheme 3.1 1,3,5-Trisubstituted diazepin-2-one synthesis. 
a% Yields a b c d 
Amide 
103 77 82 90 77 
104 55 63 
Ketone 
105 66 50(78) 60 35 
106 62 70 
Diazepine 
107 68 85 65 66 
108 71 78 
a% Yields r fer to isolated yields, yield in parentheses 
accounts for recovered starting material 
Table 3.1 Product Yields. 
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In our previous synthesis of 3,5-disubstituted 1,4-diazepin-2-ones from a-aminoacyl ~­
amino esters, the final amine deprotection 1 free-basing 1 reductive amination sequence 
gave at best 50% overall yield.5 A significant improvement in overall yield was obtained 
from performing this sequence on the corresponding tertiary amides 103 and 104 to form 
1,3,5-trisubstituted 1,4-diazepin-2-ones 107 and 108. For example, a 45% augmentation in 
overall yield was obtained from performing the Boc removal 1 reductive amination 
sequence on N-(4-benzyloxylbenzyl) amide 107b instead of the corresponding secondary 
amide. The Încrease in yield was accompanied by a noticeable acceleration in the 
reductive-amination step, which had usually occurred in 3 to 7 days in the absence of the N-
alkyl substituent. 5 In the presence of N-alkyl substituent, the reductive amination was 
typically complete after 24 h. The N-alkylation caused likely steric effects that destabilized 
the trans amide isomer and augmented the population of the cis conformer, that was 
necessary for ring formation. 27,28 Characterization of tertiary amides indicated mixtures of 
cis and trans amide isomers identified by multiple signaIs due to slow amide isomerization 
on the NMR time scale. In addition, the trisubstituted diazepinone products were less polar 
than their disubstituted counterparts and easier to purify by silica gel chromatography, 
which may also account for the better yields in the annulation sequence. 
The removal of the I-position substituent was also explored using trisubstituted 
diazepinones 107 in order to provide an alternative strategy for making 3,5-disubstituted 
diazepinone 95b. Attempts failed to remove the mercaptoethyl moieties by oxidation of the 
sul fur to the sulfone followed by ~-elimination. The presence of olefin and secondary 
amine groups in diazepinones 107c and l07d prevented selective sul fur oxidation such that 
multiple products were formed using conditions such as hydrogen peroxide in the presence 
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of catalytic amounts of ammonium heptamolybdate tetrahydrate,29 Oxone,30 and m-
INr/. TFA (95%)lTES (5%), 
RO~ 
107b: R = 4-BnO-C6H4-
109: R = 4-HO-C6H4-
,J 
HI\! NH 
O~ 
95b 
Equation 3.1 4-Benzyloxybenzylamide cleavage under acidic conditions. 
Efforts were next committed to the removal of the 4-benzyloxybenzyl group from 
diazepinone 107b. Attempts failed to remove the 4-benzyloxybenzyl protecting group 
employing oxidative conditions at room temperature, such as CAN (ceric ammonium 
nitrate)32 and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ)33 and only starting material 
107b was recovered. Trace amounts of desired diazepinone 95b and I-hydroxybenzyl 
diazepinone 109 were observed by LCMS to form at 100 oC using CAN in 
acetonitrile:water; however, decomposition ensued on prolonged exposure of diazepinone 
107b to these conditions. 
Altematively, deprotection of the 4-benzyloxybenzyl group was successfully accompli shed 
under acidic conditions. Starting material remained unaffected using trifluoroacetic acid 
(TF A) in DCM (1: 1) at room temperature after 2 days. Employment of a 95: 5 mixture of 
TF A/triethylsilane (TES)34 at room temperature for 1 day gave sorne diazepinone 95b along 
with its I-hydroxybenzyl counterpart 109. After stirring under the TFA/TES conditions at 
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80° C for 3 days, diazepinones 109 and 95b were respectively isolated in 25% and 70% 
yields after purification by column chromatography (Eq 3.1). 
3.4 Conclusion 
1,4-Diazepin-2-ones with substituents at the 1-, 3- and 5-positions of the heterocycle have 
been synthesized by an effective method featuring the copper-catalyzed cascade addition of 
vinyl Grignard reagent to N-alkyl N-Boc-a-aminoacyl p-amino esters 103a-d and 104a,b. 
Trisubstituted diazepinones 107a-d and 108a,b were respectively synthesized from 
phenylalanine and lysine to provide diversity at the 3-position. Furthermore, a variety of 1-
position substituents were introduced by reductive aminations of different aldehydes onto 
the p-amino ester precursor. A cursory study of the removal of the l-position thioethyl and 
benzyl amide substituents demonstrated that the 4-benzyloxybenzyl group may be cleaved 
under acid conditions to pro vide an alternative route to 3,5-disubstituted 1,4-diazepin-2-
ones. A study to extend this approach for generating a library of diazepinones is currently 
in progress in our laboratory. 
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3.6 Experimental Section 
a-Amino acid derivatives were N-protected usmg di-tert-butyl dicarbonate in 
dioxane:water 1: 1.35 Reagent-grade solvents were purified and dried by passage through 
solvent filtration systems prior to use. For reactions performed under anhydrous conditions, 
glassware was either oven- or flame-dried and the reaction was performed under a positive 
pressure of argon. Column chromatography was performed on silica gel (230-400 mesh) 
and thin layer chromatography (TLC) was performed on glass plates coated with (0.2 mm) 
silica gel, using the indicated solvent system. Proton (and carbon) NMR spectral data were 
collected at 300 MHz (75 MHz) and 400 MHz (100 MHz). Proton chemicals shifts (8) were 
reported in parts per million (ppm) and referenced to the residual solvent peak at 7.26 ppm 
in CDCh, unless otherwise noted. The l3C NMR spectra were reported in ppm, and 
referenced to the residual solvent peak at 77 ppm in CDCh, unless otherwise noted. 
Coupling constants J are reported in Hz. The NMR spectra of tertiary amides 103-106 
exhibited usuaIlY a mixture of amide isomers, the minor isomer signaIs for which are 
denoted by an asterisk. Melting points were determined with a capillary melting point 
apparatus and are uncorrected. High Resolution Mass Spectrometry (HRMS) was 
performed by Electrospray Ionisation (ESI). 
General Proto col 1, Synthesis of Secondary Amine 102. 
A 100 mL flask was charged with 1% acetic acid in DMF (c 0.8 M), P.alanine methyl 
ester hydrochloride salt (12 mmol, 200 mol%) and a magnetic stir bar. To the flask, 
NaBH(OAc)3 (12 mmol, 200 mol%) was added generating a white turbid suspension, that 
was stirred for 10 minutes and treated dropwise with a solution of the respective aldehyde 
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(6 mmol, 100 mol%, c 0.4 M) in DMF. The suspension was stirred for 1 hour. Completion 
of the reaction was monitored by TLC examining the disappearance of aldehyde (10% 
EtOAc in hexanes). The volatiles were then removed on a rotary evaporator. The residue 
was partitioned between saturated aqueous NaHC03 solution (50 mL) and ether (l00 mL). 
The aqueous phase was separated and extracted with ether (3 x 50 mL). The combined 
organic phase was dried over magnesium sulphate, filtered and evaporated to a residue that 
was purified on silica gel using the specified solvent as e1uant, as described below, to afford 
secondary amino esters l02a-d as oils. 
MethyI3-N-(2,4-dimethoxybenzyl)aminopropanoate (102a). 
Amine l02a was prepared from aldehyde 101"a (6 mmol, 1.08 g) according to the general 
protocol 1 and isolated in 85% yield after purification on silica gel using 5% MeOH/DCM 
as eluant: Rf 0.28 (5% MeOHIDCM). IH NMR Ô 2.56 (t, J= 6.5, 2H), 2.87 (t, J= 6.5, 2H), 
3.68 (s, 3H), 3.75 (s, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 6.44 (br m, 2H), 7.13 (d, J= 7.9, IH). 
BC NMR Ô 174.0, 161.1, 159.5, 131.3, 120.8, 104.6,99.4,56.2,56.1, 52.4,49.4,44.9, 
35.1. HRMS (El) m/z 254.1397 [M+Hf; ca1cd for C13H20N04: 254.1387. 
MethyI3-N-(4-benzyloxybenzyl)aminopropanoate (102b). 
Amine l02b was prepared from aIdehyde lOt"b (6 mmoI, 0.996 g) according to the 
general protocol 1 and isolated in 93% yield after purification on silica gel using 5% 
MeOH/DCM as eluant: Rf 0.38 (5% MeOHlDCM). IH NMR 92.58 (m, 2H), 2.91 (t, J = 
6.5, 2H), 3.68 (s, 3H), 3.71 (s, 2H), 5.06 (s, 2H), 6.93-7.45 (m, 9H). l3C NMR Ô 174.1, 
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158.8, 137.9, 132.5, 130.3, 129.4, 128.8, 128.3, 115.8, 70.9, 53.8, 52.7, 45.0, 34.6. HRMS 
(El) m/z 300.1597 [M+Ht; calcd for ClsH2IN03: 300.1594. 
Methyl 3-(2-(benzylthio )ethylamino )propanoate (1 02e). 
Amine I02e was prepared from aldehyde IOI"e (6 mmol, 0.997 g) according to the general 
protocol 1 and isolated in 80% yield after purification on silica gel using 3% MeOHIEtOAc 
as eluant: Rf 0.11 (3% MeOHIEtOAc). IH NMR 8 2.51 (t, J = 6.4, 2H), 2.59 (t, J = 6.8, 
2H), 2.77 (t, J = 6.4, 2H), 2.86 (t, J = 6.8, 2H), 3.70 (s, 3H), 3.73 (s, 2H), 7.28-7.33 (m, 
5H). \3C NMR 8 172.7, 138.0, 128.5, 128.2, 126.7, 51.3, 47.7, 44.3, 35.7, 34.1, 31.1. 
HRMS (El) m/z 254.1209 [M+Ht; ca1cd for C\3H I9N02S: 254.1211. 
MethyI3-(2-(phenylthio )ethylamino )propanoate (102d). 
Amine l02d was prepared from aldehyde lOl"d (6 mmol, 0.913 g) according to the general 
protocol 1 in 70% yield, after purification on siIica gel using 3% MeOHIEtOAc as eluant: 
Rf 0.11 (3 % MeOHIEtOAc). IH NMR 8 2.52 (t, J = 6.8, 2H), 2.78 (t, J = 6.8, 2H), 2.85 (t, 
J= 6.4, 2H), 3.01 (t, J= 6.8, 2H), 3.08 (t, J= 6.8, 2H), 3.32-3.33 (m, 1H), 7.20-7.42 (m, 
5H). \3C NMR 8 172.7, 135.3, 129.3, 128.6, 125.9,51.3,47.7,44.2,34.1,33.7. HRMS (El) 
m/z 240.1053 [M+Ht; calcd for CI2H17N02S: 240.1057. 
Chapter 3 76 
General Protocol 2, Synthesis of Tertiary Amides 103a-d and 104a,b. 
N-Boc-a-Amino acid (N-(Boc)-Phe or N-(Boc)-ro-(Cbz)-Lys, 2.2 mmol) and HATU (2.2 
mmol) were placed in a 100 mL round bottom flask, dissolved in DMF (c 0.4 M), cooled to 
o oC, treated with DIEA (4.4 mmol), stirred for 10 min under argon and treated with a 
solution of secondary amine 102 (2 mmol) in DMF (c 0.8 M). The reaction mixture was 
stirred ovemight at room temperature. The solvent was concentrated on a rotary evaporator, 
and the reduced volume was partitioned between an aqueous HCI solution (10%, 50 mL) 
and ether (50 mL). The aqueous phase was separated and extracted with ether (3 x 20 mL). 
The combined organic phase was washed with saturated aqueous NaHC03 (2 x 30 mL) and 
brine (2 x 50 mL), dried over magnesium sulphate, filtered and evaporated to a residue, that 
was purified on silica gel using the specified solvent as eluant to afford respectively tertiary 
amide 103a-d, 104a or 104b. 
(2S)-Methyl-N-(2,4-dimethoxybenzyl)-N-[ (Boe )-phenylalaninyl]-(3-alaninate (1 03 a) 
A colorless oil was prepared from amine 102a (2 mmol, 0.506 g) according to the general 
protocol 2 and isolated in 77% yield after purification on silica gel eluting with 40% EtOAc 
Ihexane, (RjO.4, 40% EtOAclhexane). lH NMR (1.6:1 isomer ratio, 400 MHz, CD30D) ô 
* * * 1.39 (s, 9H), 1.4 (s, 9H), 2.4 (m, 2H), 2.45 (m, 2H), 2.90-2.93 (m, 2H), 2.95-2.95 (m, 
2H), 3.42-3.50 (m, 2H), 3.59*(s, 3H), 3.60 (s, 3H), 3.74 (s, 6H), 3.78 (s, 6H), 4.24-4.70 (m, 
2H), 5.0 (br d, IH), 6.41-7.20 (m, 8H). BC NMR (2:1 isomer ratio, 100 MHz, CD30D) ô 
.. . . ... . 
172.4, 172.0, 171.9, 171.3, 160.7, 160.2, 158.2, 158.1 , 155.6, 155.2, 136.7 , 136.5, 
* * * * * * 129.5 , 129.3, 128.9, 126.2, 126.0 , 116.4 , 115.8, 103.9 , 103.8, 97.9, 97.4 , 78.8 , 78.7, 
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54.2,51.7,46.7,42.6·,42.2·,41.4,38.8·,38.2,32.2,31.1, 27.1. [a]D20 -7.1° (c 0.008 M, 
CHCh). HRMS (El) m/z 523.2425 [M+Na+; calcd for C27H36N207Na: 523.2429]. 
(2S)~Methyl N~( 4~(benzyloxy)-benzyl)-N-[ (Boe )phenylalaninyl]-~-alaninate (103b). 
A white solid (mp 82-83 OC) was prepared from amine l02b (2 mmol, 0.6 g) according to 
the general protocol 2, purified on silica gel eluting with 40% EtOAc/hexane (Rf 0.34, 40% 
EtOAc/hexane), and isolated in 82% yield. IH NMR (1.3:1 isomer ratio, 400 MHz, 
CD30D) () 1.36 (s, 9H), 1.40· (s, 9H), 2.44-2.48 (t, J = 8 Hz, 2H), 2.86-2.2.91 (m, 2H), 
2.92~2.93· (m, 2H), 3.44-3.51 (m, 2H), 3.57· (s, 3H), 3.59 (s, 3H), 4.39-4.86 (m, 2H), 4.79-
4.82 (br t, IH), 5.01 (s, 2H), 6.86-7.40 (m, 14H). 13C NMR (1:1 isomer ratio, 100 MHz, 
CD30D) () 172.5·, 172.3, 171.9, 171.3·, 156.0, 157.8·, 155.7·, 155.5, 136.9, 136.8, 136.4·, 
128.9, 128.8, 128.6, 128.3, 127.8, 127.2, 126.8, 126.2·, 126.1, 114.5, 114.3·, 78.9·, 78.8, 
6 • 20 ° 1 9.2, 51.6, 50.5 , 50.4,41.9, 38.3, 32.1, 31.1, 27.1. [a]D -7.1 (c 0.012 M, CHC 3). 
HRMS (El) m/z 547.2807 [M+Ht; calcd for C32H3SN206: 547.2803. 
(2S)~ Methyl N-(2-benzylthio )-ethyl-N-[ (Boe )-phenylalaninyl]-~-alaninate (103e). 
A white solid (mp 73-74 OC) was prepared from amine l02e (2 mmol, 0.506 g) according to 
the general protocol 2, purified on silica gel eluting with 25% EtOAc/hexane (Rf 0.2, 25% 
EtOAc/hexane), and isolated in 90% yield. IH NMR (1.7:1 ratio of amide isomers, 400 
MHz, CD30D) () 1.39 (s, 9 H), 1.41·(s, 9 H), 2.28~2.5 (m, 4 H), 2.85-2.98 (m, 2 H), 3.2 (br, 
1 H), 3.33-3.42 (m, 2 H), 3.51 (m, 1 H), 3.67 (s, 3 H), 3.74 (s, 2 H), 3.75· (s, 2 H), 4.60-
4.71 (m, 1 H), 6.83-7.35 (m, 10 H). 13C NMR (1.7: 1 ratio of amide isomers, 100 MHz, 
• • CD30D) () 172.3 , 171.9, 171.3, 155.5, 138.3, 138.1 , 136.4, 128.8, 128.4, 128.4, 127.8, 
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* *' • * * 127.7, 126.4, 126.3, 126.2 , 78.8, 51.5 , 50.5, 47.1, 42.9 , 42.3, 38.2, 35.1 , 34.9 , 32.2, 
3 "6 20 0 ( 1.2, 28.4, 27.0 , 2 .9. [a]o 3.23 c 0.015 M, CHCh). HRMS (El) m/z 501.2418 
(2S)-Methyl N-(2-phenylthio)-ethyl-N-[(Boc)-phenylalaninyl]-p-alaninate (103d). 
A colorless oil was prepared from amine l02d (2 mmol, 0.478 g) according to the general 
protocol 2, purified on silica gel using 25% EtOAclhexane (Rf 0.26, 25% EtOAclhexane), 
and isolated in 77% yield. IH NMR (1:1 amide isomer ratio, 300 MHz, CD30D) 8 1.39 (s, 
9H), 1.43* (s, 9H), 1.86 (m, 2H), 2.48-3.01 (m, 4H), 3.23-3.37(m, 3H), 3.49-3.54 (br t, IH), 
3.63 (s, 3H), 4.49-4.72 (m, 1H), 6.75-7.45 (m, lOH). 13C NMR (1:1 isomer ratio, 75 MHz, 
*' *' * * CD30D) 8 173.7,173.1,172.5 ,156.7,137.6,137.2,136.6,135.6,130.8, 130.1,129.9, 
* * * * * 129.7, 129.6, 129.2 , 129.0, 127.4, 127.3 , 126.5, 80.0 , 79.9, 52.8 , 51.7,47.1,44.6 ,43.7, 
39.3, 33.6*, 32.5, 31.7*, 30.3, 28.2. [a]o20 5.440 (c 0.016 M, CHCh). HRMS (El) m/z 
(2S)-Methyl-N-[E-N-Cbz-a.-N-(Boc)-lysinyl]-N-(2,4-dimethoxybenzyl)-p-alaninate 
(104a). 
A colorless oil was prepared from amine l02a (2 mmol, 0.506 g) according to the general 
protocol 2, purified on silica gel eIuting with 50% EtOAclhexane (Rf 0.24, 50% 
EtOAclhexane), and isolated in 55% yield. IH NMR (1:1 isomer ratio, 400 MHz, CD30D) 
8 1.44-1.45 (br, 17H), 2.41-2.54 (m, 2H), 3.08-3.01 (m, 2H), 3.49-3.53 (m, 2H), 3.55 (s, 
3H), 3.57* (s, 3H), 3.78" (s, 3H), 3.80 (s, 3H), 3.81 (s, 3H), 4.89 (s, 2H), 5.07 (s, 2H), 6.47-
7.35 (m, 8H). l3C NMR (1.5:1 isomer ratio, 100 MHz, CD30D) 8 173.0, 172.1, 160.9, 
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158.3, 157.0, 136.7, 129.4, 127.7, 127.2, 127.0, 115.9, 103.9*, 103.7, 97.8, 97.4*, 78.6, 
* 20 65.5,54.1,50.4,47.9,47.7,42.1,41.5,39.7,32.4,31.9, 31.1, 28.8, 27.0, 22.2 ,22.0. [a]D 
-20.4° (c 0.02 M, CHCI3). HRMS (El) m/z 616.3230 [M+Ht; calcd for C32~5N309: 
616.3229. 
(2S)-Methyl N-[ m-Cbz-N-(Boc )lysinyl]-N-( 4-(benzyloxy)benzyl)-{3-alaninate (1 04b). 
A white solid (mp 77-79 OC) was prepared from amine l02b (2 mmol, 0.6 g) according to 
the general protocol 2, purified on silica gel eluting with 30% EtOAc/toluene (Rf 0.2, 30% 
EtOAc/toluene), and isolated in 63% yield. IH NMR (1: 1 isomer ratio, 400 MHz, CD30D) 
cS 1.26-1.66 (br, 17H), 2.53-2.57 (m, 2H), 2.72-2.8* (m, 2H), 3.06-3.55 (m, 2H), 3.55-3.63 
(m, 2H), 3.68 (s, 3H), 4.46-4.69 (m, 2H), 4.89 (s, 2H), 5.07 (s, 2H), 6.75-7.42 (m, 14). l3C 
NMR (1:1 isomer ratio, 100 MHz, CD30D) cS 173.4*, 173.3, 172.0, 171.5*, 158.1, 157.9*, 
157.1, 156.0*, 136.9, 136.7, 129.0, 128.6, 128.4, 127.9, 127.7, 127.2, 127.1, 127.0, 126.8, 
114.5, 114.3*,78.7,69.2,65.5,50.5,50.3,42.2,42.1*,39.7,39.6, 32.4, 31.1,28.7,26.7, 
22.2,22.1*. [a]D20 -7.9° (c 0.026 M, CHCh). HRMS (El) m/z 662.3438 [M+Ht; calcd for 
General Proto col 3, Synthesis of Ketones l05a-d and l06a,b. 
A suspension of CuCN (0.3 mmol, 60 mol%) in THF (2 mL of THF per 1 mmol CuCN) 
was cooled to -45 oC, treated with vinyl magnesium bromide (3 mmol, 600 mol%, c 1 M) 
over 10 min, stirred for 1 h, treated with a solution of the corresponding ester l03a-d, l04a 
or l04b (0.5 mmol, 100 mol%) in THF (0.1 M), stirred for 2 h at -45 oC, and warmed to 
room temperature for an additional 30 min. The reaction mixture was cooled to 0 oC, 
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treated with a saturated ammonium chloride solution (30 mL) and shaken vigorously for 20 
min. The layers were separated, and the aqueous phase was extracted with Et20 (3 x 50 
mL) or EtOAc (3 x 50 mL). The combined extracts were washed with saturated sodium 
bicarbonate solution (50 mL), pH 6.8 phosphate buffer (50 mL) and brine (2 x 50 mL), 
dried over magnesium sulfate and concentrated under vacuum. The crude product was 
purified by column chromatography with an eluant of EtOAc in hexane as specified for 
each compound. Evaporation of the collected fractions afforded the respective ketone 
105a-d, 106a or 106b. 
(2S)-N' -(2,4-Dimethoxybenzyl)-N' -1-(3-oxohept-6-enyl)-N-(Boc )-phenylalaninamide 
(105a). 
A colorless oil was prepared from ester 103a (0.5 mmol, 0.25 g) according to the general 
protocol 3, purified on silica gel eluting with 30% EtOAc/hexane (Rf 0.2, 30% 
EtOAclHexane), and isolated in 66% yield: 1 H NMR (1.3: 1 isomer ratio, 400 MHz, 
CD30D) ô 1.39 (s, 9H), 1.42* (s, 9H), 2.16-2.53 (m, 6H), 2.89-2.92 (m, 2H), 3.33-3.41(m, 
2H), 3.42-3.76* (m, 2H), 3.77 (s, 6H), 4.86 (s, 2H), 4.93-5.03 (m, 3H), 5.76-5.80 (m, IH), 
6.41-7.23 (m, 8H). BC NMR (2:1 isomer ratio, , 100 MHz, CD30D) ô 210.0, 209.2·, 
.. ., *' .. • ., 173.7 , 173.2, 161.9, 161.4 , 159.4, 159.2, 156.8, 156.5 , 137.9, 137.8 , 130.5, 130.4 , 
* • * 130.2, 130.1 , 129.8, 129.0, 128.9, 127.4, 127.2, 117.6, 117.0, 115.1, 99.0, 98.6, 80.0, 
... *.. 20 0 79.9, 55.4 , 55.3,42.5 ,42.2,41.9,41.6,40.7,39.9 ,28.2,28.1 . [a]o -7.82 (c 0.011 M, 
CHCh). HRMS (El) m/z 525.2957 [M+W; calcd for C30H40N206: 525.2959]. 
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(2S)-N-(Boe )Phenylalanine-N' -( 4-(benzyloxy) benzyl)-N' -1-(3-oxohept-6-enyl)amide 
(10Sb). 
A colorless oil was prepared from ester 103a (0.5 mmol, 0.273 g) according to the general 
protocol 3, and purified on silica gel eluting with 30% EtOAclhexane (Rf 0.29, 30% 
EtOAclhexane). First to elute was the starting ester l03b (0.076 g, 28%). Second to elute 
was ketone 10Sb (0.143 g, 50%): tH NMR (1:1 isomer ratio, 400 MHz, CD30D) ô 1.37 (s, 
• • - * 9H), 1.42 (s, 9H), 2.17-2.42 (m, 2H), 2.56-2.40 (m, 2H), 2.42-2.48 (m, 2H), 2.56-2.60 
(m, 2H), 2.83-2.95 (m, 2H), 3.02-3.08* (m, 2H), 3.32-3.50 (m, 2H), 4.33-4.55 (m, 2H), 
4.73-4.80 (m, IH), 4.90 (s, 2H), 4.93-4.99 (br t, 2H), 5.04 (s, 2H), 5.71-5.83 (rp., IH), 6.90-
7.42 (m, 14H). 13C NMR (1:1 isomer ratio, 100 MHz, CD30D) ô 208.8, 208.0*, 172.5, 
* * * 172.2 , 158.0 , 157.7, 155.7 , 155.5, 137.0, 136.8, 136.7, 136.5, 129.0, 128.9, 128.4, 127.9, 
• • • • 127.8,127.1,126.8,126.2,126.0,114.5 , 114.2, 113.9,78.8,69.3 ,69.2,51.7,51.5,41.1 , 
41.0, 40.4, 39.4, 38.2, 27.0. [a]D20 -1.10 (c 0.01 M, CHCh). HRMS (El) m/z 571.3169 
(2S)-N-(Boe)-Phenylalanin-N' -( (2-benzylthio )ethyl)-N' -1-(3-oxohept-6-enyl)amide 
(IOSe). 
A colorless oil was prepared from ester 103e (0.5 mmol, 0.25 g) according to the general 
protocol 3, purified on silica gel eluting with 25% EtOAclhexane (Rf 0.34, 25% 
EtOAclhexane), and isolated in 60% yield. IH NMR (1.7:1 isomer ratio, 400 MHz, 
CD30D) ô 1.38 (s, 9H), 1.40* (s, 9H), 2.26-2.31 (br q, 2H), 2.43-2.53 (m, 6H), 2.82-3.01 
(m, 2H), 3.01-3.20 (m, 2H), 3.32-3.38 (m, IH), 3.74 (s, 2H), 3.78* (s, 2H), 4.58-4.66 (m, 
• 13 IH), 4.97-5.15 (m, 2H), 5.71-5.77 (m, IH), 5.78-5.88 (m, lH), 7.15-7.37 (m, lOH). C 
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NMR (2:1 isomer ratio, 100 MHz, CD30D) 8 209.1, 208.4", 172.7, 172.5*, 155.9, 155.8*, 
138.7, 138.5", 137.1, 137.0, 136.8, 129.3, 129.2*, 129.0, 128.8, 128.7*, 128.2, 128.1", 
126.8, 126.7", 126.6, 114.3, 79.2, 51.9, 51.7*, 46.2, 42.4", 41.8, 41.5", 41.4, 41.0, 40.5, 
38.6, 35.5*' 35.3, 27.4*, 26.2. [a]D20 2.70 (c 0.04 M, CHCh). HRMS (El) m/z 525.2786 
(2S)-N-(Boc)-Phenylalanin-N'-( (2-phenylthio )-ethyl)-N' -1-(3-oxohept-6-enyl)-amide 
(10Sd). 
A colorless oi1 was prepared from ester 103d (0.5 mmo1, 0.243 g) according to the general 
protocol 3, purified on silica gel eluting with 25% EtOAc/hexane (Rf 0.34, 25% 
EtOAc/hexane), and isolated in 35% yie1d. I H NMR (1.2:1 isomer ratio, 400 MHz, 
CD30D) 8 1.40 (s, 9H), 1.43* (s, 9H), 2.24-2.27 (m, 2H), 2.41-2.56 (m, 4H), 2.80-2.97 (m, 
4H), 3.18-3.57 (m, 4H), 5.7-5.86 (m, IH), 4.95-5.04 (m, 2H), 5.78-5.81 (m, IH), 7.0-7.89 
(m, lOH). 13C NMR (1.8: 1 isomer ratio, 100 MHz, CD30D) 8 208.7, 207.9*, 172.5, 172.4*, 
. " .. ,. 155.6, 155.5 , 136.7, 136.6 , 136.4, 136.1 , 135.4, 134.5 , 129.5, 128.9, 128.7 , 128.5, 
128.4*, 128.0, 127.9*, 127.8, 126.3*, 126.2, 126.1, 125.3, 114.0, 78.8*, 77.7, 59.8, 51.7*, 
,.,. "* 20 0 51.5,46.2,42.3,41.1,41.0,39.7,38.2 ,30.6 ,29.1,27.0. [a]D 4.1 (c 0.008 M,CHCl). 
(2S)-N-(Boc )-N s-(Cbz)-Lysin-N' -(2,4-dimethoxybenzyl)-N' -1-(3-oxohept-6-enyl)-
amide (106a). 
A colorless oil was prepared from ester 104a (0.5 mmol, 0.308 g) according to the general 
protocol 3, purified on silica gel eluting with 40% EtOAc/hexane (Rf 0.15, 40% 
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EtOAc/hexane), and isolated in 62% yield. 'H NMR (1.1:1 isomer ratio, 400 MHz, 
CD30D) 0 1.29-1.45 (m, 17H), 2.22-2.26 (t, J = 6.9, 2H), 2.43-2.45 (m, 2H), 2.55-2.67* (m, 
2H), 3.08-3.10 (m, 2H), 3.48" (m, 2H), 3.62-3.64"(m, 2H), 3.76* (s, 3H), 3.78 (s, 3H), 3.8 
(s, 3H), 4.54 (br s, 2H), 4.65-4.74 (m, 1H), 4.86 (s 2H), 4.93-4.98 (m, 2H), 5.06 (s, 2H), 
5.77-5.79 (m, 1H), 6.92-7.3 (m, 8H). l3C NMR (2.7:1 isomer ratio, 100 MHz, CD30D) () 
209.0, 208.2", 173.2", 172.9, 172.0, 160.8, 160.2*, 158.3, 158.1\ 157.06, 156.l", 155.8, 
• * * • 136.7, 129.4, 129.3 , 127.7, 127.2, 127.0, 116.5 , 116.0, 113.9, 103.9 , 103.7, 97.8, 97.5 , 
* • • * • 78.7, 78.6, 65.5, 54.2, 54.1 ,50.5, 42.9, 41.2 , 41.1 ,41.0,40.8,40.6,39.9 ,39.5,31.9, 
" * 20 0 31.3 ,28.8,27.0,22.2,22.1. [a]o -17.6 (c 0.012 M, CHCi)). HRMS (El) m/z 640.3591 
(2S)-N-(Boc )-N s-(Cbz)-Lysin-N' -( 4-(benzyloxy)benzyl)-N' -1-(3-oxohept-6-enyl)-
amide (106b). 
A colorless oil was prepared from ester l04b (0.5 mmol, 0.331 g) according to the general 
protocol 3, purified on silica gel eluting with 40% EtOAc/hexane (Rf 0.17, 40% 
EtOAc/hexane), and isolated in 70% yield. 'H NMR (1:1 isomer ratio, 400 MHz, CD30D) 
o 1.24-1.66 (m, 17H), 2.23-2.26 (br t, 2H), 2.39-2.49 (m, 2H), 2.60-2.72" (m, 2H), 2.84 (br 
s, lH) 3.04-3.13 (br d, 2H), 4.34-4.67 (m, 2H), 4.88 (s, 2H), 4.93-4.98 (t, J = 9.76, 2H), 
5.05 (s, 4H), 5.73-5.83 (m, IH), 6.71-7.40 (m, 14 H). BC NMR (1.3:1 isomer ratio, 100 
MHz, CD]OD) 0 209.0,208.2",173.4*,173.2,158.1, 157.8*, 157.2, 157.1", 156.2, 156.0*, 
136.9, 136.8, 136.7, 129.2, 128.7, 128.5, 127.9, 127.8, 127.7, 127.2, 127.1, 127.0, 126.8, 
• • ' * 78.7,69.2,65.5,50.6,50.4 ,41.5,41.1 ,41.0,40.5,39.8,39.6,39.5,31.3,28.7,27.0,22.2 , 
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22.1. [a]D20 -9.5° (c 0.042 M , CHCh). HRMS (El) m/z 686.3802 [M+Ht; ca1cd for 
C4oH51N307: 686.3800. 
General Protocol 4, Synthesis of 1,3,5-Trisubstituted 1,4-Diazepinones 107a-d and 
108a,b. 
Ketone .l05a-d, 106a or 106b (0.095 mmol, 100 mol%) was dissolved in a 1:1 TFAlDCM 
solution (4 mL), stirred for 10 min, and evaporated to a residue. The residue was dissolved 
in THF (5.10-3 M), treated with supported free tertiary amine Amberlyste A-21 resin (1.9 
mmol, 2000 mol%, prewashed with methanol, THF, DCM and dried under high vaccum for 
2 h), stirred for 2 h, filtered and treated with a sodium cyanoborohydride solution in THF 
(0.475 mmol, 500 mol%, c 1 M). The reaction mixture was stirred ovemight under argon 
atmosphere. After completion of the reaction was indicated by TLC, the solvent was 
concentrated on a rotary evaporator, and the remainder was partitioned between a saturated 
NaHC03 solution (20 mL) and ethyl acetate (20 mL). The aqueous phase was separated and 
extracted with ethyl acetate (3 x 10 mL). The combined organic phase was dried over 
magnesium sulphate, filtered and evaporated to a residue, which was purified further as 
specified below. 
(3S,5S)-3-Benzyl-5-but-3-enyl-l-(2,4-dimethoxybenzyl)-[ 1,4] diazepin-2-one (1 07 a). 
A colorless oil was prepared from ketone 105a (0.095 mmol, 0.05 g) according to the 
general protocol 4, purified on silica gel eluting with 20% EtOAc/hexane (Rf 0.22, 20% 
EtOAc/Hexane), and isolated in 68% yield. I H NMR (400 MHz, CDCh) 8 1.18-1.34 (m, 
3H), (m, IH), 1.78 (m, 2H), (m, IH), 2.83-2.89 (q, J= 8, IH), 3.28-3.33 (m, 2H), 3.57-3.60 
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(m, 2H), 3.81 (s, 6H), 4.51-4.68 (q, J= 16, 2H), 4.7-4.84 (m, 2H), 5.56-5.57 (m IH), 6.46-
6.49 (m, 2H), 7.25-7.35 (m, 6H).J3C NMR (100 MHz, CDCh), cS 174.4, 159.8, 158.1, 
138.9, 137.5, 130.8, 129.0, 128.1, 126.0, 118.0, 114.4, 103.9, 97.9, 60.6, 59.8, 55.0, 55.9, 
46.9,45.2,37.8,35.7,35.3,29.4. [a]D20 -7.60 (c 0.018, CHCh). HRMS (El) m/z 409.2491 
[M+H+; calcd for C2sH32N203: 409.2486]. 
(3S,5S)-3-Benzyl-1-( 4-benzyloxybenzyl)-5-(bu t-3-enyl)-1,4-diazepin-2-one (1 07b). 
A colorless oïl was prepared from ketone 105b (0.095, 0.054 g) according to the general 
protocol 4, purified on silica gel eluting with 30% EtOAclhexane (Rf 0.24, 30% 
EtOAclhexane), and isolated in 85% yield. lH NMR (400 MHz, CDCb) cS 1.28-1.34 (m, 
3H), 1.46 (m, IH), 1.76 (m, 2H), 2.3 (m, IH), 2.89 (q, J = 4.0, IH), 3.3.1-3.58 (m, 2H), 
3.56-3.62 (m, 2H), 4.57-4.59 (q, J = 8, 2H), 4.69-4.89 (m, 2H), 5.08 (s, 2H), 5.51-5.61 (m, 
IH), 6.95-6.97 (d, J 8, 2H), 7.24-7.47 (m, 12H). BC NMR (100 MHz, CDCh), cS 174.3, 
157.8, 138.6, 137.4, 136.6, 129.7, 129.3, 129.2, 129.0, 128.2, 127.6, 127.1, 126.1, 115.1, 
114.5,69.7, 60.7, 59.8, 50.4, 46.4, 37.7, 35.6, 35.2, 29.4. [a]D20 -41.80 (c 0.079, CH2C}z). 
HRMS (El) m/z 455.2707 [M+Ht; calcd for C30H34N202: 455.2693. 
(3S,5S)-3-Benzyl-1-( (2-benzyltbio )ethyl)-5-(but-3-enyl)-1,4-diazepin-2-one (1 07c). 
A colorless oil was prepared from ketone 105c (0.095 mmol, 0.048 g) according to the 
general proto col 4, purified on silica gel eluting with 10% EtOAc/CHCh (Rf 0.22, 10% 
EtOAc/CHCh), and isolated in 65% yield. lH NMR (400 MHz, CDCh) cS 1.28-1.37 (m, 
4H), 1.65-1.67 (m, 4H), 2.6-2.64 (m, 2H), 3.22-3.24 (m, 2H), 3.50-3.6. (m, 4H), 3.79 (s, 
2H), 4.67-4.85 (m, 2H), 5.55-5.57 (m, IH), 7.25-7.38 (m, IOH). l3C NMR (100 MHz, 
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CDCh), (5 174.2, 138.5, 138.0, 137.4, 129.0, 128.6, 128.2, 126.7, 126.2, 114.6, 60.6, 59.8, 
48.1, 48.0, 37.6, 35.8, 35.7, 35.6, 35.6, 29.4, 28.9. [a]n20 -37.6° (c 0.03, EtOH). HRMS 
(El) m/z 409.2326 [M+Ht; calcd for C2SH32N20S: 409.2308. 
(3S,5S)-3-Benzyl-l-«2-phenylthio )ethyl)-5-(but-3-enyl)-1,4-diazepin-2-one (107d). A 
colorless oil was prepared from ketone 105d (0.095 mmol, 0.047 g) according to the 
general protocol 4, purified on silica gel eluting with 20% EtOAclhexane (Rf 0.22, 20% 
EtOAclhexane), and isolated in 66% yield. IH NMR (400 MHz, CDCh) (5 1.28-1.39 (m, 
2H), 1.41-1.76 (m, 4H), 2.48 (br s, IH), 2.81-2.85 (m, IH), 3.1-3.29 (m, 4H), 3.44-3.47 (m, 
4H), 4.68-4.84 (m, 2H), 5.52-5.59 (m, IH), 7.19-7.42 (m, lOH). l3C NMR (100 MHz, 
CDCh), (5 174.3, 138.5, 137.4, 135.4, 129.0, 128.7, 128.4, 128.2, 126.2, 125.6, 114.6,60.5, 
59.8, 49.1, 48.9, 37.5, 35.8, 35.6, 30.7,29.3. [a]n20 -23.16° (c 0.043, CHCh). HRMS (El) 
m/z 395.2171 [M+H]\ calcd for C24H30N20S: 395.2152. 
(3S,5S)-1-(2,4-Dimethoxybenzyl)-3-( 4-N-(Cbz )-aminobu tyl)-5-(but-3-enyl)-1,4-
diazepin-2-one (108a). 
A colorless oil was prepared from ketone l06a (0.095 mmol, 0.061 g) according to the 
general protocol 4, purified on silica gel eluting with 70% EtOAclhexane (Rf 0.21, 70% 
EtOAclhexane), and isolated in 71% yield. IH NMR (300 MHz, CDCh) 81.40-1.65 (m, 
lOH), 2.13 (m, 2H), 2.74 (br d, IH), 3.20-3.42 (m, 4H), 3.52 (m, IH), 3.80 (s, 6H), 4.42-
4.47 (d, J = 14.5, IH), 4.61-4.66 (d, J = 14.7, IH), 4.97 (br t, 2H), 5.10 (s, 2H), 5.79-5.80 
(m, IH), 6.44 (br d, 2H), 7.21-7.38 (m, 7H). l3C NMR (75 MHz, CDCh), (5 175.5, 161.0, 
159.3, 157.3, 139.1, 137.6, 132.0, 129.3, 128.9, 128.8, 119.1, 115.7, 105.1,99.2,67.3,61.0, 
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60.2, 56.2, 47.8, 46.3, 41.6, 37.0, 36.1, 33.0, 31.1, 30.6, 30.5, 24.4. [a]D20 -8.70 (c 0.013, 
CHCh). HRMS (El) m/z 524.3119 [MHt; calcd for C30~lN305: 524.3110. 
(3S,5S)-I-( 4-Benzyloxybenzyl)-3-( 4-N-( Cbz )-aminobutyl)-5-(but-3-enyl)-1,4-diazepin-
2-one (108b). 
A colorIess oit was prepared from ketone 106b (0.095 mmol, 0.065 g) according to the 
general protocol 4, purified on silica gel eluting with 70% EtOAc/hexane (Rf 0.24, 70% 
EtOAclhexane), and isolated in 78% yield. lH NMR (300 MHz, CDCh) ô1.27-1.61 (m, 
WH), 2.08-2.13 (m, 2H), 3.20-3.40 (m, 4H), 3.57 (br q, IH), 4.40-4.45 (d, ) =14.4, IH), 
4.62 (d, )=14.4, IH), 4.95-5.04 (m, 2H), 5.05 (s, 4H), 5.10 (s, 2H), 5.76 (m, IH), 6.92 (d, 
) 8.4, 2H), 7.19 (d, ) = 8.7, 2H), 7.28-7.469 (m, WH). l3C NMR (75 MHz, CDCh), ô 
174.7, 159.0, 157.3, 138.8, 137.8, 137.5, 130.8, 130.7, 130.5, 129.4, 129.3, 129.1, 128.8, 
128.3, 116.0, 115.8, 70.9, 67.4, 61.1, 60.2, 51.5, 47.2, 41.5, 36.5, 35.5, 32.7, 31.0, 30.6, 
24.3. [a]D20 _8.1 0 (c 0.095, CHCb). HRMS (El) m/z 570.3344 [M+Ht; calcd for 
C35~3N304: 570.3326. 
(3S,5S)-3-Benzyl-5-but-3-enyl-l,4-diazepin-2-one 95b and 3-benzyl-5-but-3-enyl-l-( 4-
hydroxy-benzyl)-[1,4 ]diazepin-2-one (109). 
4-Benzyloxybenzyl amide 107b (12 mg, 0.026 mmol) was placed into a 10 mL three 
necked flask, equipped with a water condenser, treated with 3 mL of a mixture of TF AlTES 
(95:5), and heated with an oil bath to a bath temperature of 80 oC for 72 h. The progress of 
the reaction was followed by LCMS analysis, by removing aliquots from the mixture and 
injecting directly onto a Gemini column (C18 110 A, 50x4.60 mm, 511) and analyzed with 
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an eluant of 20-80% acetonitrile:H20 buffered with 0.1 % TF A. After 72h, a 75 :25 ratio was 
observed of three peaks eluting at retention times of 3.49 and 4.24 min corresponding to 
3,5-disubstituted diazepinone 95b and 4-hydroxybenzylamide 109. The solution was cooled 
to room temperature, and concentrated under vacuum to a residue, that was purified on 
silica gel using 50% EtOAc/hexane as eluent, to afford diazepinone 109 (2.4 mg, 25% 
yield) as a colorless oil, Rf 0.25 (50% EtOAc/hexanes). I H NMR (400 MHz, CD Ch) ù 
1.29-1.47 (m, 2H), 1.6-1.93 (m, 4H), 2.02-2.22 (m, 4H), 3.20-3.24 (br d, IH), 3.75-3.82 (br 
q, IH), 4.50-4.62 (m, 2 H), 5.02-5.10 (m, 2H), 5.75-5.83 (m, IH), 6.70-7.39 (m, 9H). BC 
NMR (100 MHz, CDCh), Ù 174.3, 165.7, 156.5, 135.8, 135.6, 129.0, 128.8, 127.8, 126.5, 
126.2, 114.8, 114.6, 60.4, 58.6, 43.9, 34.7, 32.0, 30.1, 28.6. HRMS (El) m/z 365.2228 
[M+H+; ca1cd for C23H28N2023: 365.2224]. [a]D20 -7.0° (c 0.014, CHCh). Second to elute 
was diazepinone 95b5 on changing the solvent system to 5% methanol/DCM. After 
evaporation of the combined collected fractions, the residue was dissolved in 10% HCI 
solution followed by freeze drying to afford diazepinone 95b5 (5.0 mg, 70% yield): mp 
138-140 oC; Rf 0.32 (5% MeOHlDCM), [a]D20 -35.0° (c 0.008, DMF). HRMS (El) m/z 
259.1808 [M+H+; ca1cd for C16H23N20: 259.1804]. Ref 5 : mp 138-140 oC; [aJo20 -35.6° (c 
0.008, DMF). 
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Chapter 4 
Concluding Statements and Future Work 
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4.1. Introduction 
Since the first report of solid phase peptide synthesis by Merrifield in 1963,1 the solid-
phase-synthesis method has become a common practice in the academic and industrial 
settings, because it can serve as an efficient and powerful tool for preparing organic 
molecules.2 The solid-phase method offers many advantages over the conventional 
solution-phase approaches, primarily because of the convenient work-up and purification of 
intermediates during synthesis.3 
Attractive targets due to their well-known biological properties, the 1,4-benzodiazepin-2-
ones were among the first classes of small molecules to be synthesized on sol id supports.4 
Many syntheses of similar skeletons on solid support have since been reported.4,5 For 
example the synthesis of a benzodiazepin-2-one library has been achieved using an acid 
labile traceless linker composed of supported germanium 110 (Scheme 4.1).6 Palladium-
catalyzed cross coupling of resin bound aryl stanane 110 with an acyl chloride, aniline 
deprotection, followed by acylation with a series of Fmoc amino acids, Fmoc deprotection, 
and cyclization afforded resin supported benzodiazepin-2-one 113. Benzodiazepinone 114 
and bromobenzodiazepinone 115 were respectively cleaved from the resin by treatment 
with trifluoroacetic acid and bromine. 
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Me J-R1 
(S\ ___ /3,eVNHMPc ~-Chlorobenzo[1 ,2,3]dioxalborane 
\!JfI- Me IPr2EtN, DCM 
111 ~~----------------_. 
~R1 N R2 ~e - - X . qe ~ /; N 0 @--I Me R3 113 1) R2CH(NHFmoc)COF 2) Piperidine 3) AcOH 4) Base, R3X 
Br2' DCM / J TFA, 60 Oc ~R1 N R2 / <;Rl N R2 - - - X Bc ~ - h ~Xo H ~ h ~, a 
R3 114 R 115 
o 
~ ~OU R1 = Ethyl, benzyl, acetamide, 3,5-dimethylbenzyl 
\:iIJJ ~ 1 R2 = isopropyl, benzyl, 4-hydroxybenzyl, t-butylacetyl 
\. 0 O~ R3 = admantyl, naphtyl, 4-methoxyphenyl, y 3-methoxyphenzyl, 3,4-dimethoxyphenyl. 
r\ 
\J Mpc = 2-(-4-methylphenyl)isopropyl carbamate 
Scheme 4.1 Synthesis of l,4-benzodiazepine derivatives using germanium-linker. 
A second benzodiazepinone synthesis strategy involved ring closure between C3 and N4 by 
a conjugate addition on a resin bound fumarate. 7 Wang resin 116 was treated with fumaryl 
chloride to fumish the supported acyl chloride 117. Mesylate 119 was prepared by 
acylation of aminobenzyl a1cohol118 first with the fumaryl chloride resin 117, followed by 
methanesulfonyl chloride. 1,4-Benzodiazepin-2-ones 121 were then produced by 
intermolecular displacement of mesylate 119 with different primary amines, intramolecular 
7-exo-trig cyclization by conjugate addition, and cleavage by transesterification with 
sodium methoxide (Scheme 4.2) 
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~OH fumaryl chloride 
• 
116 
R1 = CI, Br, OMe 
o 
CII~O 
o l~ 
117 'W 
121 
R2 = Methyl, terbutyl, isopropyl, phenyl, 4-methylphenyl, 4-methoxyphenyl 
R3 = benzyl,4-fluorobenzyl, 2-methylfuranyl,2-methylthiophenyl, 4-chlorobenzyl 
95 
Scheme 4.2 Synthesis oftetrahydro-l,4-benzodiazepin-2-one by intramolecular 7-exo-trig 
cyclization. 
In adopting our solution-phase synthesis to solid support, a sulfide safety-catch linker was 
examined for the synthesis of 1,4-diazepin-2-ones (Scheme 4.4), because of its successful 
use in the solid-phase synthesis of other heterocycles. The P-sulfide group can be activated 
on oxidation to a sulfone and cleaved by p-elimination un der basic conditions.8 Such a 
strategy has been utilized for the synthesis of peptides,8,9 carboxylic acids,lo esters, Il 
amines,12 nucleic acids 13 and heterocycles such as diketopiperazines, JO benzopurans 14 and 
pyrrolopyrimidines. 15 In addition, desulfurisation by breaking the C-S bond was considered 
for making N-ethyl diazepinone. In addition to the thioethyl amide linker, alkoxybenzyl 
amide linkers were explored, because they had already proven suitable for solid-phase 
diazepine synthesis. For example, a library of 1,4-diazepin-2,5-diones (2058 compounds) 
was prepared by a strategy employing a 2,4,6-trialkoxy benzyllinker (Scheme 4.3). 6 
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NH2 HOC~ R3AC02Me 
NaH(OAch. DMF 
122 
[ 
0 ~J RcC-t~3 
126 
ct<~~ 
RI N~ , 0 
127 R
2 
Gt= 
Scheme 4.3 1,4-Benzodiazepin-2,5-dione synthesis using 2,4,6-trialkoxybenzyllinker. 
a-Amino esters were linked to benzaldehyde support 122 by a reductive amination 
employing sodium triacetoxybrohydride in DMF to provide amine 123, which was acylated 
with various substituted anthranilic acids 124 using EDC as activating agent. Treatment of 
the resulting dipeptide 125 with the lithium salt of acetanilide followed by alkylation 
afforded the alkyl substituted 1,4-diazepin-2,5-dione 127, which was cleaved from the resin 
on treatment with TFA:Me2S:H20 (90:5:5). In light of the sucees of solid phases synthesis 
for preparing librairies of 1,4-benzodiazepin-2-one derivatives, the adaptation of our 
solution-phase methodology to a solid-phase strategy was envisioned to prepare 
diazepinones librairies. Two strategies were pursued using different linker techinques. 
Initially, a thioethyllinker was explored to attach the ~-amino ester to the support with the 
objective of cleaving the heterocycle by an oxidationl~-elimination sequence. 
Subsequently, an acid labile benzyllinker was used to make the 1,4-diazepin-one core. 
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4.2. Attempted Solid-Phase Synthesis of 1,4- Diazepin-2-one Using 
Thioethyl and 4-Alkoxybenzyl Linkers 
Resin-bound aldehyde 128a was prepared from amino ethyl polystyrene resin and 4-
(dimethoxyethylthio )benzoic acid using diisopropylcarbodimide and HOBt followed by 
acetal deprotection using dioxane/2N HCL 8 A second resin-bound aldehyde 128b was 
prepared by thiol alkylation with 2-bromo-l, I-dimethoxyethane, followed by acetal 
hydrolysis. Resin-bound aldehydes 128a and 128b were characterized by IR spectroscopy, 
which showed an aldehyde stretching band at 1722 cm-1 for 128a and at 1718 cm-1 for 
128b. Aldehyde loadings of 0.2 mmollg and 0.7 mmollg were determined by elemental 
analysis of resins 128a and 128b by measurement of sulfur content using elemental 
analysis. Resin-bound amines 130a-b were synthesized by the reductive amination of the 
imine from ~-alaninate 129 and the respective aldehyde resin 128a-b employing 
NaBH(OAc)3 in a 1 % acetic acid in DMF solution.6 
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Completion of the reaction was ascertained when the aldehyde stretch was no longer 
observed at respectively 1722 and 1718 cm- I for resins 128a and 128b using IR analysis; 
moreover, a new stretching band appeared at 1738 and 1729 cm- I corresponding to the 
respective methyl esters. Acylation of the resuIting secondary amine 130a-b with N-Boc-
phenylalanine using HA TU in DMF provided tertiary amide 132a-b.16 In the FTIR spectra, 
a new streching band at 1709 and 1736 cm- I was observed. Attempts to cleave the 
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dipeptide from the resin to determine loading and purity were, however, unsuccessful using 
trifluoromethane sulfonate. Acylation was examined· qualitatively by Boc group 
deprotection using TFA: DCM (1:1) and a ninhydrin test l7 which showed a positive blue 
colour. In the IH MAS-NMR (magic angle spinning-NMR) spectrum singlets were 
observed at ~ 1.4 and 3.45 ppm which corresponded to the Boc tert-butyl group and 
methyl ester, and may be used to assess the reaction conversion from the starting amino 
ester with signal at 3.45 ppm. Resin bound homoallylic ketone 133a-b was synthesized by 
treating tertiary amide 132a-b with freshly prepared vinyl magnesium bromide (2000 
mol%) in the presence of copper cyanide (500 mol%) in THF at -45 °C. 18 Ketone formation 
was indicated by the weak carbonyl C=Q streching band at 1709 cm-1 in the FT-IR 
spectrum of resin 133a-b in compressed in KBr tablets. Moreover, large stretching bonds 
observed at 3429 and 3431 cm-1 indicated the formation of tertiary alcohol. Supported 1,4-
diazepin-2-one 134a-b was prepared from a sequence of reactions initiated by Boc group 
removal using either TFA:DCM (1:1) or SiCl4 (c lM, 2000 mol%) and phenol (3M, 6000 
mol%) in DCM. 19 Intramolecular imine formation was achieved by neutralization of the 
TF A salt using triethylamine; imine reduction was then achieved using sodium 
cyanoborohydride in THF buffered with 1 % acetic acid. The progress of the sequence was 
monitored by ninhydrin test which showed the disappearance of the primary amine. In 
addition, FT-IR spectroscopy indicated the ketone C=Q stretching band at 1709 cm-I had 
disappeared. 
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For the cleavage of the diazepinone product, sulfone resins 135a-b were pursued by 
oxidation of the sulfur using either Oxone in DCE/DMF 4: 1 or m-CPBA in DCM.8 The IR 
spectroscopy showed a superposition of the sulfone band with alkane band this result 
suggesting that the sulfur may have not been completely oxidized to sulfone. Attempts 
failed to liberate diazepinone 95b from oxidized resins 135a-b in THF using respectively 
LDA, DBU, NaMeO, KtBuO, and KHMDS (600 mol%) to effect p-elimination. Similarly, 
attempts failed to liberate diazepinone 136 by desulfurization employing respectively 5% 
Na/Hg20 in methanol, SmI2/DMAP in THF and SmI2/tBuOH in THF21 In aIl' cases, no 
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product was observed by LCMS analysis (Eq. 4.1). Finally, using SmI2/DMAP on resin 
135b trace amounts of a peak having correct mass for 95b were observed by LCMS 
analysis. The presence of free amine, the possibility of incomplete sulfur oxidation and the 
poor swelling property of the linker in polar sol vents such as methanol, aIl may have 
inhibited the release of the desired compound from the linker. 
Resin-bound aldehyde 137 was prepared by alkylation of Merrifield resm with 4-
methoxybenzaldehyde employing NaOH in DMF at 80 °C.22 Conversion of the aldehyde 
137 to supported secondary amine 138 was achieved by a reductive amination of the imine 
produced on treatmeant of the resin with ~-alanine methyl ester using sodium 
triacetoxyborohydride in DMF containing a catalytic amount of acetic acid.6 The reductive 
amination reaction was monitored by a dinitrophenyl hydrazine test which showed 
colourless beads after disappearence of aldehyde23 and by IR spectroscopy following the 
disappearance of the aldehyde stretch at 1681 cm- l . A loading of 1.0 mmol/g was 
determined by elemental analysis ofresin 138 and by measurement ofnitrogen content. 
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The N-(Boc)-Phenylalanine was coupled to secondary amine 138 using HATU and DIEA 
in DMF. The progress of the reaction was monitored by chloranil test which involves 
reacting of the secondary amine 138 with equal amounts of solutions of acetaIdehyde and 
tetrachloro-p-benzoquinone. Upon heating the colour changed from green to blue due to the 
presence of a complex between the secondary amine 138, acetaldehyde and tetrachloro-p-
benzoquinone.23 After acylation no change in the colour was observed by the chloranil test 
indicate of the fomation of amide. Homoallylic ketone 140 was prepared by a similar 
method as described for ketone 133, in which the vinyl magnesium bromide and copper 
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cyanide were mixed in THF for at least 1 hour at -45 oC, and then added over 15 minutes to 
the mixture containing the swollen ester resin 139 in THF. 18 Ketone resin 140 exhibited a 
sharp band at 1707 cm-1 corresponding to carbonyl bond in its FTIR-spectrum. Supported 
diazepinone 141 was prepared by the same method as described for diazepinone 134, 
initiated by Boc group removal using either TFA:DCM (1:1) or SiCl4 (c lM, 2000 mol%) 
and phenol (c 3M, 6000 mol%) in DCM. Intramolecular imine formation was achieved by 
neutralization of the TF A salt using triethylamine; imine reduction was performed using 
sodium cyanoborohydride in THF buffered with 1 % acetic acid. The progress of the 
sequence was monitored by the Kaiser test,17 which showed the disappearance of the 
primary amine by changing the blue colour of beads to colourless. Diazepinone 142, was 
c1eaved from the solid support using TFA:TES 95:5,24 and by using 4M HCI in dioxane. 
The cru de product was obtained in 80% purity as esteemed by HPLC analysis after 
c1eavage from the supported 1,4-diazepin-2-one 141 using TFA:TES 95:5. Purification of 
the crude product on silica gel chromatography afforded diazepinone 109 in 18% overall 
yield from the supported amine 138. 
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4.3 Conclusion and Perspectives 
Solid-phase synthesis of 1,4-diazepin-2-one has been pursued using two different strategies 
for linking the amide to the solid phase. The thioethyl linker strategies may have provided 
diazepinone; however, an effective c1eavage strategy for removing the 1,4-diazepin-2-one 
from the solid supports could not be achieved. Diazepinone was prepared by an approach 
using 4-alkoxybenzaldehyde resin 137. Furthermore, potential may now exist to make 
diazepinones on solid support possessing greater diversity at the 5-7 positions by 
employment of substituted p-amino esters and vinyl Grignard reagents.26 In summary, an 
effective acid labile linker strategy has been developed for the synthesis of enantiopure 1,4-
diazepin-2-one from inexpensive amino acid building blocks. This method offers potential 
for synthesis of libraries of diazepinones with interesting pharmaceutical properties. 
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4.4 General Procedure for The Synthesis of 1,4-Diazepinone. 
A typical procedure for the generation of 1,4-diazepinone follows. 
Synthesis of secondary amine resin 130a-b and 138. The reductive amination of 
aldehyde derived resin was performed as follows: to a polyethylene 20 mL tube charged 
with 1 g of resin (128a-b and 137) was added 6 equiv of p-alanine methyl ester 
hydrochloride and 6 equiv of sodium triacetoxyborohydride dissolved in a minimum 
volume of DMF buffered with 1 % acetic acid, the reaction mixture was vigorously shaken. 
Completion of the reaction was monitored by IR spectroscopy after 20 min, by analysis of 
an aliquot of the resin, which was removed and rinsed with DMF (3 x 5 mL), CH30H (3 x 
5 mL) and DCM (3x 5 mL). Completion of the reaction was verified by DNPH test, (IR 
data, 1738, 1729 and 1728 cm-1). 
Loading : 0.2 mmol/g for resin 128a according to sulfur microanalysis found C, 87.35; H, 
7.43: N, 0.80, S, 0.94, 0.5 mmol/g for resin 128b according to sulfur microanalysis found 
C, 87.25; H, 7.47: N, 1.29, S, 2.55 and 1.0 mmol/g for resin 138 according to nitrogen 
microanalysis found C, 85.03; H, 7.67: N, 1,38. 
Synthesis of tertiary amide resin 132a-b and 139. 
N-(Boc)Phenylalanine or what (400 mol%), was dissolved in a minimum amount ofDMF, 
cooled to 0 oC, treated with DIEA (800 mol%) followed by HATU (400 mol%), stirred for 
5 min under argon, and the mixture was added to swollen secondary amine resin (128a-b 
and 138, 500 mg) in DMF (6 mL). The reaction mixture was shaken for 12 hours at room 
temperature, filtered, and the resin was washed with DMF (3 x 20 mL), THF (3 x 20 mL), 
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MeOH (3 x 20 mL) and DCM (3 x 20 mL). Completion of the reaction was verified by 
chloranil test, (IR data, 1736, 1734 and 1737 cm-') 
Homoallylic ketone resin 133a-b and 140. 
In a flame-dried, three-neck round bottom flask with a mechanical stirrer and an argon 
in let, resin (500 mg, 132a-b and 139) was swollen in THF (6 mL), treated with copper 
cyanide (500 mol%), cooled to -45 oC, treated dropwise with a freshly prepared solution of 
vinyl magnesium bromide (2000 mol%, c lM in THF), stirred over night during which time 
the bath temperature warmed to room temperature. The resin mixture was cooled to -45 oC, 
treated with with saturated ammonium chloride solution shaken vigorously for 20 minutes, 
filtered then washed with water (3 x 60 mL), DMF (3 x 20 mL), THF (3 x 20 mL), CH30H 
(3 x 20 mL) and DCM (3 x 20 mL) and then dried under vaccuo to give ketone resin (133a-
band 140). The formation of ketones was confirmed by DNPH test, (IR data, 1709 cm- l 
weak signal and 1707 cm-1). In order to prevent aggregation ether or ethyle acetate with 
saturated ammonium chloride solution were added in the first step ofwashing. 
Diazepinone resin 134a-b and 141: Ketone resin 133a-b and 140 (250 mg) was first 
exposed for 5 min to a solution of silicon tetrachloride lM (2000 mol%) and phenol 3 M 
(6000 mol%) in DCM to effect Boc deprotection, which was qua1itatively indicated by a 
positive blue colour Kaiser test. The resin was then rinsed with DCM:Et3N 9: 1 (3 x 20 mL), 
DCM (3 x 20 mL) and THF (3 x 20 mL). The deprotected resin was swollen in THF (4 
mL) buffered with 1 % acetic acid and treated with sodium cyanoborohydride (600 mol%). 
The reaction was continued until the Kaiser Test showed colourless beads. The resin was 
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rinsed wÎth THF (3 x 20 mL), DMF (3 x 20 mL) and DCM (3 x 20 mL). In the IR spectrum 
ofresin 134a-b and 141, the ketone stretch was no longer observed at 1709 and 1707 cm"l. 
Sulfone Resin 135a-b: In three-neck round bottom flask with a mechanical stirrer, 
diazepinone resin 134a-b (250 mg) was swollen in DMF/H20 (3.2 mL: 0.8 mL) for 15 min 
at room temperature, treated with Oxone (0.275 mg, 1500 mol%), and stirred at room 
temperature for 18 h. The resin was filtered, washed with DMF (3 x 20 mL), water (3x 
20mL), THF (3 x 20 mL), and DCM (3 x 20 mL) and dried in vaccuo. 
(3S,5S)-3-Benzyl-5-but-3-enyl-1,4-diazepin-2-one (95b) : 
Diazepinone resin 135b (100 mg) was swollen in THF (4 mL) for 15 minutes in a 10 mL 
polyethylene tube. DMPU (0.17 mL, 8.4 mmol), and a solution of SmI2 (2.2 mL, c 0.1 M in 
THF, 3.7 mmol) were added and the reaction mixture was allowed to stir at room 
temperature for 18 h at room temperature. The resin was filtered and the solution phase was 
collected and concentrated in vaccuo. Only trace of compound 95b was observed by LCMS 
analysis. Rf 0.32 (5% MeOHlDCM). LRM [M+H+; calcd for C16H22N20: 259.2] 
(3S,5S)-3-Benzyl-5-but-3-enyl-l-( 4-hydroxy-benzyl)-[1 ,4] diazepin-2-one (109). 
Diazepinone resin 141 (150 mg) was swollen in DCM (4 mL) in a 10 mL polyethylene 
tube, treated with 4mL of a mixture of TF AlTES (95: 5) at room temperature for 24 h. The 
resin was filtred and washed with TFA (2 x 5 mL) and DCM (2 x 5 mL). The filtrate was 
concentrated under vacuum to a residue, that was purified by flash column chromatography 
using 50% EtOAc/hexane as eluent to afford diazepinone 109 (10 mg, 18% overall yield) 
as colorless oil, Rr0.25 (50% EtOAc/hexane). IH NMR (400 MHz, CDCh) Ô 1.29-1.47 (m, 
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2H), 1.6-1.93 (m, 4H), 2.02-2.22 (m, 4H), 3.20-3.24 (br d, IH), 3.75-3.82 (br q, IH), 4.50-
4.62 (m, 2 H), 5.02-5.10 (m, 2H), 5.75-5.83 (m, IH), 6.70-7.39 (m, 9H). 13C NMR (100 
MHz, CDCh), Ù 174.3, 165.7, 156.5, 135.8, 135.6, 129.0, 128.8, 127.8, 126.5, 126.2, 114.8, 
114.6,60.4, 58.6,43.9, 34.7, 32.0, 30.1,28.6. HRMS (El) m/z 365.2228 [M+H+; ca1cd for 
C23H28N202: 365.2224]. [a]o20 -7.0° (c 0.014, CHCb). 
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5.1 Conclusion 
Inverse y-tum conformations have been implicated in the biological activity of peptides 
such as Leu-enkephalin, angiotensin II, bradykinin, urotensin-II and oxytocin. 1 The 
introduction of 1,4-diazepin-2-ones into peptide mimic libraries may provide active 
candidates in structure-activity relationship studies because of their potential to mimic y-
tums. The development of a new synthetic approach for building 1,4-diazepin-2-one 
heterocycles has been achieved from N-substituted and unsubstituted u-aminoacyl p-amino 
esters by a sequence featuring copper catalyzed cascade addition of vinyl Grignard to the 
corresponding ester, Boc removal, amine neutralisation and finally reductive amination. 
Alkene double bond oxidation of the homoallylic ketone followed by Boc removal and 
neurtralisation of the amine with supported base (Amberlyste A-21) yielded 
pyrrolodiazepinones. A small family of diazepinones and pyrrolodiazepinones has been 
synthesized to demonstrate this methodology. 
The seven membered heterocyclic mimetics were synthesized from two buildings blocks: a 
N-Boc-a-amino acid and p-amino-ester. The reductive amination was slow in the case of 
dipeptide; however, conversion of the secondary into tertiary amide caused a noticeable 
acceleration in the cyclisation step to provide 1,3,5-trisubstituted 1,4-diazepin-2-ones. This 
approach allowed for the introduction of new diversity at Nj, by employing acid labile 
nitrogen susbstituent, the 1,3,5-trisubstituted 1,4-diazepin-2-one, could be converted to its 
3,5-disubstituted counterpart. For the application of this methodology to solid phase we 
have focused on phenyl, benzylthioethyl and acid labile linkers. 
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The efficiency of pheny1 and benzylthioethyl linkers was eva1uated in solution and solid 
suppport, LCMS ana1ysis showed traces of 1,4-diazepin-2-one after re1ease from 
benzylthioethyllinker. In addition we demonstrated that the use of acid labile linker proved 
a more promising approach to prepare 1,3,5-trisubstituted and 3,5-disubstituted 1,4-
diazepin-2-ones as confirmed in the 1ast chapter. In the future this approach may allow for 
the preparation of of y-tum mimics libraries libraries for styding peptide chemistry and 
biology. 
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